FALSE000021741031 December30 June, 20242024Q2iso4217:EURiso4217:EURxbrli:sharesxbrli:purexbrli:sharesul:brandiso4217:GBPxbrli:sharesiso4217:USDxbrli:shares00002174102024-01-012024-06-3000002174102023-01-012023-06-300000217410ifrs-full:IssuedCapitalMember2023-12-310000217410ifrs-full:SharePremiumMember2023-12-310000217410ul:UnificationReservesMember2023-12-310000217410ifrs-full:OtherReservesMember2023-12-310000217410ifrs-full:RetainedEarningsMember2023-12-310000217410ifrs-full:EquityAttributableToOwnersOfParentMember2023-12-310000217410ifrs-full:NoncontrollingInterestsMember2023-12-3100002174102023-12-310000217410ifrs-full:RetainedEarningsMember2024-01-012024-06-300000217410ifrs-full:EquityAttributableToOwnersOfParentMember2024-01-012024-06-300000217410ifrs-full:NoncontrollingInterestsMember2024-01-012024-06-300000217410ifrs-full:OtherReservesMember2024-01-012024-06-300000217410ifrs-full:IssuedCapitalMember2024-06-300000217410ifrs-full:SharePremiumMember2024-06-300000217410ul:UnificationReservesMember2024-06-300000217410ifrs-full:OtherReservesMember2024-06-300000217410ifrs-full:RetainedEarningsMember2024-06-300000217410ifrs-full:EquityAttributableToOwnersOfParentMember2024-06-300000217410ifrs-full:NoncontrollingInterestsMember2024-06-3000002174102024-06-300000217410ifrs-full:IssuedCapitalMember2022-12-310000217410ifrs-full:SharePremiumMember2022-12-310000217410ul:UnificationReservesMember2022-12-310000217410ifrs-full:OtherReservesMember2022-12-310000217410ifrs-full:RetainedEarningsMember2022-12-310000217410ifrs-full:EquityAttributableToOwnersOfParentMember2022-12-310000217410ifrs-full:NoncontrollingInterestsMember2022-12-3100002174102022-12-310000217410ifrs-full:RetainedEarningsMember2023-01-012023-06-300000217410ifrs-full:EquityAttributableToOwnersOfParentMember2023-01-012023-06-300000217410ifrs-full:NoncontrollingInterestsMember2023-01-012023-06-300000217410ifrs-full:OtherReservesMember2023-01-012023-06-300000217410ifrs-full:IssuedCapitalMember2023-06-300000217410ifrs-full:SharePremiumMember2023-06-300000217410ul:UnificationReservesMember2023-06-300000217410ifrs-full:OtherReservesMember2023-06-300000217410ifrs-full:RetainedEarningsMember2023-06-300000217410ifrs-full:EquityAttributableToOwnersOfParentMember2023-06-300000217410ifrs-full:NoncontrollingInterestsMember2023-06-3000002174102023-06-300000217410ul:BeautyAndWellbeingMember2023-04-012023-06-300000217410ul:PersonalCareMember2023-04-012023-06-300000217410ul:HomeCareMember2023-04-012023-06-300000217410ul:NutritionMember2023-04-012023-06-300000217410ul:IceCreamMember2023-04-012023-06-3000002174102023-04-012023-06-300000217410ul:BeautyAndWellbeingMember2024-04-012024-06-300000217410ul:PersonalCareMember2024-04-012024-06-300000217410ul:HomeCareMember2024-04-012024-06-300000217410ul:NutritionMember2024-04-012024-06-300000217410ul:IceCreamMember2024-04-012024-06-3000002174102024-04-012024-06-300000217410ul:BeautyAndWellbeingMember2023-01-012023-06-300000217410ul:PersonalCareMember2023-01-012023-06-300000217410ul:HomeCareMember2023-01-012023-06-300000217410ul:NutritionMember2023-01-012023-06-300000217410ul:IceCreamMember2023-01-012023-06-300000217410ul:BeautyAndWellbeingMember2024-01-012024-06-300000217410ul:PersonalCareMember2024-01-012024-06-300000217410ul:HomeCareMember2024-01-012024-06-300000217410ul:NutritionMember2024-01-012024-06-300000217410ul:IceCreamMember2024-01-012024-06-300000217410ul:AsiaPacificAfricaMember2023-04-012023-06-300000217410srt:AmericasMember2023-04-012023-06-300000217410srt:EuropeMember2023-04-012023-06-300000217410ul:AsiaPacificAfricaMember2024-04-012024-06-300000217410srt:AmericasMember2024-04-012024-06-300000217410srt:EuropeMember2024-04-012024-06-300000217410ul:AsiaPacificAfricaMember2023-01-012023-06-300000217410srt:AmericasMember2023-01-012023-06-300000217410srt:EuropeMember2023-01-012023-06-300000217410ul:AsiaPacificAfricaMember2024-01-012024-06-300000217410srt:AmericasMember2024-01-012024-06-300000217410srt:EuropeMember2024-01-012024-06-300000217410ul:K18Member2024-02-010000217410ul:ElidaBeautyMember2024-06-010000217410ul:ElidaBeautyMember2024-06-012024-06-010000217410ifrs-full:TopOfRangeMember2024-02-082024-02-0800002174102024-05-172024-05-170000217410ifrs-full:DerivativesMember2024-06-300000217410ifrs-full:DerivativesMember2023-12-310000217410ifrs-full:DerivativesMember2023-06-300000217410ul:OtherFinancialAssetMember2024-06-300000217410ul:OtherFinancialAssetMember2023-12-310000217410ul:OtherFinancialAssetMember2023-06-300000217410ul:JudicialDepositsMember2024-06-300000217410ul:JudicialDepositsMember2023-12-310000217410ul:JudicialDepositsMember2023-06-300000217410ifrs-full:AtFairValueMember2024-06-300000217410ifrs-full:AtFairValueMember2023-12-310000217410ifrs-full:AtFairValueMember2023-06-300000217410ul:CarryingValueMember2024-06-300000217410ul:CarryingValueMember2023-12-310000217410ul:CarryingValueMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMember2023-06-300000217410ul:CarryingValueMemberifrs-full:DerivativesMember2024-06-300000217410ul:CarryingValueMemberifrs-full:DerivativesMember2023-12-310000217410ul:CarryingValueMemberifrs-full:DerivativesMember2023-06-300000217410ifrs-full:AtFairValueMemberul:OtherFinancialAssetMember2024-06-300000217410ifrs-full:AtFairValueMemberul:OtherFinancialAssetMember2023-12-310000217410ifrs-full:AtFairValueMemberul:OtherFinancialAssetMember2023-06-300000217410ul:CarryingValueMemberul:OtherFinancialAssetMember2024-06-300000217410ul:CarryingValueMemberul:OtherFinancialAssetMember2023-12-310000217410ul:CarryingValueMemberul:OtherFinancialAssetMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level1OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level2OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level1OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level2OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level1OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level2OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMemberul:OtherFinancialAssetMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberul:OtherFinancialAssetMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberul:OtherFinancialAssetMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMemberul:OtherFinancialAssetMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberul:OtherFinancialAssetMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberul:OtherFinancialAssetMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMemberul:OtherFinancialAssetMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberul:OtherFinancialAssetMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberul:OtherFinancialAssetMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level1OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level2OfFairValueHierarchyMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:DerivativesMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level1OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level2OfFairValueHierarchyMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:DerivativesMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level1OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:DerivativesMemberifrs-full:Level2OfFairValueHierarchyMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:DerivativesMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2024-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2023-12-310000217410ifrs-full:AtFairValueMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2023-06-300000217410ifrs-full:AtFairValueMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:FinancialLiabilitiesAtFairValueMember2023-06-300000217410ul:UnileverPLCMember2024-04-012024-06-300000217410ul:UnileverPLCMemberifrs-full:OrdinarySharesMemberul:TradedOnTheLondonStockExchangeMember2024-04-012024-06-300000217410ul:UnileverPLCMemberifrs-full:OrdinarySharesMemberul:TradedOnEuronextInAmsterdamMember2024-04-012024-06-300000217410ul:UnileverPLCMemberul:AmericanDepositaryReceiptsMember2024-04-012024-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
Dated July 26, 2024
Commission File
Number: 001-04546
UNILEVER PLC
(Translation of registrant’s name into English)
UNILEVER HOUSE, BLACKFRIARS, LONDON, ENGLAND
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    UNILEVER PLC     
/S/ M VARSELLONA
BY M VARSELLONA
    CHIEF LEGAL OFFICER AND GROUP SECRETARY
Date: 26 July 2024


Logo blue RGB.jpg
Brand logos for PR Apr24.jpg
2024 First Half Results
Innovation and brand investment driving faster volume growth
Underlying performanceGAAP measures
(unaudited)2024
vs 2023
 2024
vs 2023
First Half
Underlying sales growth (USG) 4.1% Turnover€31.1bn2.3%
Beauty & Wellbeing 7.1% Beauty & Wellbeing€6.5bn5.1%
Personal Care 5.6% Personal Care€7.0bn0.6%
Home Care 3.3% Home Care€6.3bn2.0%
Nutrition 3.2% Nutrition€6.7bn1.3%
Ice Cream 0.6% Ice Cream€4.6bn2.8%
Underlying operating profit€6.1bn17.1% Operating profit€5.9bn7.8%
Underlying operating margin19.6%250bps Operating margin19.1%100bps
Underlying earnings per share€1.6216.3% Diluted earnings per share€1.475.4%
Free cash flow€2.2bn€(0.3)bnNet profit€4.0bn3.5%
Second Quarter
USG 3.9% Turnover €16.1bn2.2%
Quarterly dividend payable in September 2024€0.4396 
per share(a)
3.0%
(a) See note 9 for more information on dividends

First half highlights
•Underlying sales growth of 4.1%, with volumes up 2.6%
•Power Brands (~75% of turnover) leading growth with 5.7% USG and volumes up 4.0%
•Turnover increased 2.3% to €31.1 billion with (1.1)% impact from currency and (0.7)% from net disposals
•Underlying operating margin up 250bps to 19.6%, with gross margin up 420bps
•Brand and marketing investment up 180bps to 15.1%, focused on Power Brands
•Underlying EPS increased 16.3%, diluted EPS up 5.4%
•Quarterly dividend raised by 3%; €1.5bn share buyback commenced
•Free cash flow of €2.2 billion, reflecting seasonal working capital outflow
•Productivity programme underway and separation of Ice Cream on track
Chief Executive Officer statement
“We are focused on driving high-quality sales growth and gross margin expansion, led by our Power Brands. Over the first half, we made progress on those ambitions.
Underlying sales grew 4.1%, driven by a third consecutive quarter of positive, improving volume growth, while pricing continued to moderate in line with our expectations. Strong gross margin progression fuelled increased investment behind our innovations, and resulted in a step-up of our profitability.
We continue to embed the Growth Action Plan, doing fewer things, better and with greater impact. The implementation of a comprehensive productivity programme and the separation of Ice Cream are key to delivering on that commitment and we are progressing at pace.
There is much to do, but we remain focused on transforming Unilever into a consistently higher performing business.”
Hein Schumacher
USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
1

Outlook
We continue to expect underlying sales growth (USG) for 2024 to be within our multi-year range of 3% to 5%, with the majority of the growth being driven by volume.
Underlying operating margin for the full year is expected to be at least 18%, with increasing investment behind our brands. We expect the year-on-year margin progression in the second half to be smaller than in the first half.
Our very strong gross margin progression in the first half reflects positive contributions from volume leverage, mix and net productivity but also factors that will not repeat in the second half such as, a low prior year comparator affected by high input costs, and carry-over pricing from a period of higher inflation.

First Half Review: Unilever Group
Growth
(unaudited)TurnoverUSGUVGUPGA&DCurrencyTurnover change
First Half€31.1bn4.1%2.6%1.6%(0.7)%(1.1)%2.3%
Second Quarter€16.1bn3.9%2.9%1.0%(0.6)%(1.0)%2.2%
Underlying sales growth in the first half was 4.1%, led by volume of 2.6% and price of 1.6%. We delivered our third consecutive quarter of positive, improving volume growth, with UVG up 2.9% in Q2, increasing from 2.2% in Q1 and 1.8% in Q4 2023. Four of our five business groups delivered positive volume growth in Q2. As expected, underlying price growth continued to moderate from 2.8% in Q4 2023 to 1.0% in Q2.
The Power Brands performed strongly with 5.7% underlying sales growth, driven by volume growth of 4.0% in H1. Our other brands also saw a sequential volume improvement to (1.1)% in Q2, up from (2.0)% in Q1.
As expected, our turnover-weighted market share movement*, which measures our competitive performance within the footprint in which we operate, remained largely unchanged on a rolling 12 month-basis. We expect a sequential improvement of the share trend over time reflecting increasing benefit from the Growth Action Plan.
Beauty & Wellbeing grew underlying sales by 7.1%, with volume growth of 5.5% driven by continued double-digit growth from Health & Wellbeing and Prestige Beauty combined. In Q2, particularly strong growth in Health & Wellbeing more than offset softer growth in Prestige that reflected a slowdown in the US beauty market. Personal Care grew 5.6% with 2.9% from volume, led by continued strong sales growth of Deodorants. Home Care underlying sales increased 3.3%, with 4.6% volume growth more than offsetting the negative price growth linked to commodity cost deflation in some emerging markets. Nutrition grew underlying sales by 3.2%, driven by price with flat volume for the first half. Nutrition returned to positive volumes in Q2 at 0.4%, up from (0.4)% in Q1. Ice Cream continued to focus on operational improvements. Underlying sales growth was 0.6% with volume down (1.0)%, driven by weak sales in China and a softer start to the summer season in Europe.
Emerging markets (59% of Group turnover) grew underlying sales 5.1%, with 3.8% from volume and 1.3% from price. India grew 1.2%, with stronger volumes partially offset by price. Lower input costs led to negative price, while volumes in India sequentially improved throughout the first half, reaching 3.8% in Q2. Latin America grew 8.8%, with continued strong volume growth across the region. Africa and Turkey delivered broad-based, double-digit growth, driven by strong volume and price. Growth in South East Asia was adversely impacted by a sales decline of (5.7)% in Indonesia, where some consumers avoided the brands of multi-national companies in response to the geopolitical situation in the Middle East. China declined mid single-digit, due to market weakness across all categories apart from food service.
Developed markets (41% of Group turnover) grew underlying sales 2.8% with 0.8% from volume and 2.0% from price. The return to positive volume growth reflected a continued resilient performance in North America and a marked volume improvement in Europe, up 2.2% in Q2. As expected, price growth continued to moderate from the peak in Q2 2023.
Turnover was €31.1 billion, up 2.3% versus the prior year, including (1.1)% from currency and (0.7)% from disposals net of acquisitions.



*Turnover-weighted market share movement: global aggregate of Unilever value market share changes, weighted by the turnover of the category-country combinations

USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
2

First Half Review: Unilever Group (continued)
Profitability
(unaudited)UOPUOP growthUOM%Change in UOMOPOP growthOM%Change in OM
First Half€6.1bn17.1%19.6%250bps€5.9bn7.8%19.1%100bps
Underlying operating profit was €6.1 billion, up 17.1% versus the prior year. Underlying operating margin increased 250bps to 19.6%.
We improved gross margin by 420bps to 45.7%. Accelerating gross margin is a key focus for the business. We started to rebuild gross margin in the second half of 2023, with an improvement of 330bps and continued that momentum into the first half of 2024. The first half improvement reflects positive contributions from volume leverage, mix and net productivity but also factors that will not repeat in the second half such as, a low prior year comparator affected by high input costs, and carry-over pricing from a period of higher inflation. Improved gross margin supported a further step-up in brand and marketing investment behind a strong and focused innovation programme. Investment was up 180bps to 15.1% of turnover, an increase of €0.7 billion. Overheads reduced by 10bps, benefiting from a focus on tighter cost control.
Operating profit of €5.9 billion increased 7.8% against a prior year comparator that was boosted by higher profit on disposal.
Progress on productivity programme and Ice Cream separation
In March, we announced the separation of Ice Cream and the launch of a major productivity programme to strengthen the company and substantially improve our efficiency and effectiveness. Separation activity is underway and on track to complete by the end of 2025. We are working at pace on the legal entity set up, the standalone operating model and carve-out financials. In July, we communicated internally on the planned changes to simplify our business and further evolve our category-focused operating model. We have started consultations with the respective works councils.
Capital allocation
In February 2024, we announced a share buyback programme of up to €1.5 billion to be conducted during 2024. The first tranche of up to €850 million commenced in May.
As a result of the strong first half performance, the Board increased the quarterly interim dividend for Q2 by 3.0% to €0.4396, the first increase since Q4 2020.
We continued to reshape our portfolio, acquiring K18, a premium biotech hair care brand, in February, and completing the disposal of Elida Beauty in June. In July we announced agreements to sell our water purification businesses Pureit, to A.O. Smith, and stake in Qinyuan Group, to Yong Chao Venture Capital Co., Ltd. The deals are expected to complete in the second half of the year.

Conference Call
Following the release of this trading statement on 25 July 2024 at 7:00 AM (UK time), there will be a live webcast at 8:00 AM available on the website www.unilever.com/investor-relations/results-and-presentations/latest-results.
A replay of the webcast and the slides of the presentation will be made available after the live meeting.
Upcoming Events
DateEvents
24 October 2024Q3 2024 trading statement
22 November 2024Capital Markets Day in London
13 February 2025Q4 and FY 2024 results
USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
3

First Half Review: Business Groups
First Half 2024
Second Quarter 2024
(unaudited)TurnoverUSGUVGUPGUOM%Change in UOM
Turnover
USG
UVG
UPG
Unilever€31.1bn4.1%2.6%1.6%19.6%250bps€16.1bn3.9%2.9%1.0%
Beauty & Wellbeing€6.5bn7.1%5.5%1.5%20.0%110bps€3.4bn6.8%5.4%1.3%
Personal Care€7.0bn5.6%2.9%2.6%23.0%300bps€3.5bn6.4%4.4%1.9%
Home Care€6.3bn3.3%4.6%(1.3)%16.3%400bps€3.1bn3.4%4.9%(1.4)%
Nutrition€6.7bn3.2%–%3.2%22.3%390bps€3.3bn2.7%0.4%2.2%
Ice Cream€4.6bn0.6%(1.0)%1.6%14.6%(40)bps€2.8bn(0.5)%(1.1)%0.6%
Beauty & Wellbeing (21% of Group turnover)
In Beauty & Wellbeing, we focus on three key priorities that will drive the unmissable superiority of our brands: elevating our core Hair Care and Skin Care brands to increase premiumisation; fuelling the growth of Prestige Beauty and Health & Wellbeing with selective international expansion; and continuing to strengthen our beauty and wellbeing capabilities.
(unaudited)TurnoverUSGUVGUPGA&DCurrencyTurnover changeUOM%Change in UOM
First Half€6.5bn7.1%5.5%1.5%(0.8)%(1.2)%5.1%20.0%110bps
Second Quarter€3.4bn6.8%5.4%1.3%0.2%(0.6)%6.3%
Beauty & Wellbeing delivered another strong performance, with underlying sales up 7.1%, driven by volume up 5.5% and price up 1.5%. Power Brands led this growth with underlying sales growth of 11.3%.
Hair Care delivered mid-single digit growth with positive volume and price. Our largest hair care brand, Sunsilk grew double-digit supported by combing cream innovations across Latin America and the continued success of its 2023 relaunch. Dove grew high-single digit led by volume growth following the launch of Scalp + Hair Therapy, for improved scalp health and hair density. Clear and TRESemmé grew well with the continued expansion of our patented anti-dandruff shampoo and our new Lamellar Shine range.
Core Skin Care grew mid-single digit led by strong volume growth in our top brands. Vaseline grew strong double-digit supported by its premium ranges, including Radiant X and Gluta Hya, which continue to be rolled out to new markets. Pond’s continued to deliver high-single digit growth led by volume, following its 2023 relaunch.
Health & Wellbeing and Prestige Beauty combined delivered double-digit growth for the 14th consecutive quarter. This was led by very strong growth in Health & Wellbeing, while softer growth in Prestige Beauty reflected a slowdown in the US beauty market. Liquid IV grew strong double-digit with the continued success of its sugar-free variant, launch of new flavours supported by prominent social media campaigns, and ongoing international roll-out. Olly and Nutrafol contributed double-digit volume growth. In H1, Nutrafol extended into skin care with a daily supplement designed to address the root causes of acne and Olly drove good growth in China supported by its focus on female health supplements. Tatcha and Hourglass grew double-digit, while Paula’s Choice was affected by the market slowdown.
Underlying operating profit was €1.3 billion, up 11% versus prior year. Underlying operating margin increased 110bps to 20.0% driven by gross margin improvement, which supported a step-up in brand and marketing investment.
Personal Care (22% of Group turnover)
In Personal Care, we focus on winning with science-led brands that deliver unmissable superiority to our consumers across Deodorants, Skin Cleansing, and Oral Care. Our priorities include developing superior technology and multi-year innovation platforms, leveraging partnerships with our customers, and expanding into premium areas and digital channels
(unaudited)TurnoverUSGUVGUPGA&DCurrencyTurnover changeUOM%Change in UOM
First Half€7.0bn5.6%2.9%2.6%(3.4)%(1.4)%0.6%23.0%300bps
Second Quarter€3.5bn6.4%4.4%1.9%(4.1)%(1.6)%0.3%
Personal Care delivered balanced growth with underlying sales up 5.6%, 2.9% from volume and 2.6% from price. Performance was led by the Power Brands with 7.0% underlying sales growth.
Deodorants continued to deliver double-digit growth, with high-single digit volume growth led by Europe and Latin America. Dove grew double-digit with strong volumes and expanded into the Whole Body deodorants market.
USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
4

First Half Review: Business Groups (continued)
Rexona and Axe contributed strong volume growth with continued momentum from our multi-year innovation platforms and our Fine Fragrance range.
Skin Cleansing grew low-single digit with positive volume growth and price. Growth was tempered by deflation in India and market challenges in Indonesia. Dove delivered high-single digit growth with good growth in Dove Men+Care. Europe grew double-digit with mid-single digit volume supported by Dove’s Body Wash relaunch. In the United States, we launched a premium range of Dove Body Wash infused with skin care serums including hyaluronic acid, collagen and vitamin C.
Oral Care continued to grow mid-single digit with positive volume and price. Close Up grew high-single digit with positive volume.
Underlying operating profit was €1.6 billion, up 16% versus prior year. Underlying operating margin increased 300bps driven by gross margin recovery, supporting a step-up in marketing investment. This investment includes strategic sponsorships such as our official partnership with UEFA EURO 2024™ and CONMEBOL Copa América USA 2024™.
Home Care (20% of Group turnover)
In Home Care, we focus on delivering for consumers who want superior products that are sustainable and great value. We drive growth through unmissable superiority in our biggest brands, in our key markets and across channels. We have a resilient business that spans price points and grows the market by premiumising and trading consumers up to additional benefits.
(unaudited)TurnoverUSGUVGUPGA&DCurrencyTurnover changeUOM%Change in UOM
First Half€6.3bn3.3%4.6%(1.3)%–%(1.3)%2.0%16.3%400bps
Second Quarter€3.1bn3.4%4.9%(1.4)%–%(1.5)%1.8%
Home Care delivered underlying sales growth of 3.3%, with continued good volume growth of 4.6%, partially offset by (1.3)% price, driven primarily by emerging markets. Underlying sales growth of the Power Brands was up 3.7%.
Fabric Cleaning grew low-single digit with low-single digit volume and negative price. Growth was supported by the launch of Persil Wonder Wash, with our patented Pro-S technology, the first ever detergent designed for short cycle washes. This significant innovation has now been introduced in the UK, France and China and is on track to be rolled out to other key markets over the next 18 months. Europe grew double-digit with strong volumes. India and Brazil grew volume while price declined reflecting commodity deflation, notably in our powders portfolio.
Home & Hygiene grew high-single digit with mid-single digit volume and slightly positive price. Cif and Domestos grew double-digit with double-digit volume. In H1, we expanded Domestos Power Foam to new markets and extended the range to include specialist solutions with long-lasting fragrance and limescale removal. Cif was supported by strong performances across Latin America in its cream and sprays portfolio.
Fabric Enhancers grew high-single digit led by volume, slightly offset by negative price. Comfort grew high-single digit supported by the launch of our new, Botanicals and Elixir ranges, with our patented CrystalFresh technology, delivering 10 times more fragrance.
Underlying operating profit was €1.0 billion, up 35% versus prior year. Underlying operating margin increased 400bps as commodity deflation supported a strong gross margin recovery, funding an increase in brand and marketing investment.
Nutrition (22% of Group turnover)
In Nutrition, our strategy is to deliver consistent, competitive growth by offering unmissably superior products through our biggest brands. We do this by reaching more consumers and focusing on top dishes and high consumption seasons to satisfy consumer’s preferences on taste, health and sustainability; while delivering productivity and resilience in our supply chain.
(unaudited)TurnoverUSGUVGUPGA&DCurrencyTurnover changeUOM%Change in UOM
First Half€6.7bn3.2%–%3.2%(0.4)%(1.4)%1.3%22.3%390bps
Second Quarter€3.3bn2.7%0.4%2.2%(0.3)%(1.5)%0.9%
Nutrition underlying sales grew 3.2% in the first half, driven by price with flat volumes. Volume growth turned positive in Q2, up 0.4%. Power Brands, including Knorr and Hellmann's, which represented nearly 65% of Nutrition turnover, grew 5.2%. This performance was partially offset by volume declines of our smaller brands.
USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
5

First Half Review: Business Groups (continued)
Scratch Cooking Aids grew mid-single digit with positive volume and price, led by Knorr. Growth was supported by double-digit performance in Latin America where Knorr’s innovation and marketing focus on local top dishes continues to drive growth across the portfolio.
Dressings delivered low-single digit growth with positive volume and price. Hellmann’s grew mid-single digit with the continued strong performance of flavoured mayo that launched in additional markets and added new variants in North America and Europe. Brazil grew double-digit which was enhanced by strategic partnerships, including our second year as a sponsor of the National Basketball Association in Brazil.
Unilever Food Solutions grew high-single digit with mid-single digit volume, led by double-digit growth in China. Growth was driven by the latest edition of our Future Menu’s Trend report, sparking inspiration and sales in professional kitchens, and continued gains from our digital selling programme.
Underlying operating profit was €1.5 billion, up 23% versus prior year. Underlying operating margin increased 390bps with a strong recovery in gross margin driven by normalising commodity costs and SKU optimisation. Gross margin improvement supported an increase in brand and marketing investment.
Ice Cream (15% of Group turnover)
In Ice Cream, our immediate strategic priority is to expand operating profit and global market share. We will do this by building the unmissable superiority of our brands, accelerating market development in emerging markets, continuing to lead the industry on innovation and premiumisation, and by stepping up our performance and productivity. In March, we announced the planned separation of Ice Cream which we expect to be completed by the end of 2025. The separation will create a world-leading business, operating in a highly attractive category with five of the top 10 selling global ice cream brands.
(unaudited)TurnoverUSGUVGUPGA&DCurrencyTurnover changeUOM%Change in UOM
First Half€4.6bn0.6%(1.0)%1.6%1.9%0.3%2.8%14.6%(40)bps
Second Quarter€2.8bn(0.5)%(1.1)%0.6%1.9%0.5%2.0%
Ice Cream had a disappointing start to its key season, with underlying sales up 0.6%. 1.6% underlying price growth was partially offset by negative volume of (1.0)%.
Performance remains below our ambition, having been impacted by a soft start to the European key season and challenging market dynamics in China. In-home Ice Cream delivered flat price and volume, while out-of-home Ice Cream grew low-single digit driven by price.
Wall’s grew mid-single digit with positive volume and price, Ben & Jerry’s was slightly up, while sales of Cornetto were adversely affected by the decline in China. Magnum launched its new ‘Pleasure Express’ range with 3 variants: Euphoria, Wonder and Chill.
Ice Cream continues to focus on operational improvements, including service and optimising promotions, while continuing to drive investment behind our brands and innovations.
Underlying operating profit was €0.7 billion, flat versus prior year. Underlying operating margin declined (40)bps as gross margin improvement was offset by an increase in brand and marketing investment. Cost inflation of key commodities continued, driven by cocoa and sugar.
USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
6

First Half Review: Geographical Areas
First Half 2024
Second Quarter 2024
(unaudited)
TurnoverUSGUVGUPGTurnoverUSGUVGUPG
Unilever€31.1bn4.1%2.6%1.6%€16.1bn3.9%2.9%1.0%
Asia Pacific Africa€13.4bn3.5%2.4%1.0%€6.7bn3.4%2.4%0.9%
The Americas€11.4bn5.4%3.9%1.5%€5.9bn5.0%3.8%1.1%
Europe€6.3bn3.5%0.5%2.9%€3.5bn3.0%2.2%0.8%
First Half 2024
Second Quarter 2024
(unaudited)
TurnoverUSGUVGUPGTurnoverUSGUVGUPG
Emerging markets€18.2bn5.1%3.8%1.3%€9.2bn4.8%3.7%1.1%
Developed markets€12.9bn2.8%0.8%2.0%€6.9bn2.6%1.8%0.8%
North America€6.7bn3.4%2.0%1.4%€3.5bn3.2%2.5%0.7%
Latin America€4.7bn8.8%7.0%1.6%€2.4bn8.0%6.0%1.9%
Asia Pacific Africa (43% of Group turnover)
Underlying sales growth was 3.5% with 2.4% from volume and 1.0% from price.
India grew 1.2% as volume sequentially improved in Q2 to 3.8%. Volume was partially offset by negative price linked to lower commodity costs in several categories. China declined reflecting weaker market growth in most of our categories and low consumer confidence. Despite the overall market dynamic, Unilever Food Solutions delivered double-digit growth in China, building on its double-digit growth in H1 2023. Underlying sales declined (5.7)% in Indonesia, with negative price and volume. This largely reflects the ongoing impact of some Indonesian consumers avoiding multinational brands and the need for operational improvements.
Africa grew double-digit with positive price and volume. Turkey delivered strong double-digit volume growth in a hyperinflationary environment.
The Americas (37% of Group turnover)
Underlying sales grew 3.4% in North America with 2.0% from volume and 1.4% from price. Beauty & Wellbeing delivered volume-led high-single digit growth, driven by a strong performance in Health & Wellbeing. Personal Care grew low-single digit driven by price as we lapped a particularly strong prior year comparator in Deodorants. Nutrition grew low-single digit with positive volume and price, led by continued growth in Dressings. Ice Cream was flat with positive volume and negative price as we optimised promotions.
Underlying sales in Latin America grew 8.8% with 7.0% volume and 1.6% price. Growth was broad-based with all Business Groups. Personal Care and Beauty & Wellbeing grew double-digit with strong volumes and positive price. Home Care contributed high-single digit volume growth, which was largely offset by negative price. Nutrition grew high-single digit with positive price and volume led by Knorr and Hellmann’s. Brazil grew high-single digit led by volume, with strong volume growth in Deodorants, Dressings, and Home Care categories. Price was negative largely due to commodity deflation in Home Care. Mexico grew double-digit with all Business Groups growing volume and price. Argentina performed well in a challenging environment, delivering double-digit volume growth despite hyperinflationary pricing.
Europe (20% of Group turnover)
Underlying sales grew 3.5% with 2.9% price and 0.5% volume growth. Helped by strong innovations and a step-up in brand support, Europe delivered 2.2% volume growth in Q2. It was the first positive UVG since Q2 2021 despite a soft start of the key ice cream season. Home Care and Personal Care grew double-digit led by volume growth, which was supported by strong innovations across Domestos, Persil, and Dove. Nutrition declined low-single digit but returned to growth in Q2 with positive volume. Ice Cream declined low-single digit impacted by poor weather. The United Kingdom, Germany and Eastern Europe grew well with positive volumes.

USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
7

Additional commentary on the financial statements - First Half
Finance costs and tax
Net finance costs increased by €99 million to €358 million in 2024. This was largely driven by the higher cost of debt on bonds, a lower interest credit from pensions, partially offset by a slightly higher interest income. As a result, net finance costs were 2.9% on average net debt. For full year 2024, we now expect net finance costs of around 3% on average net debt.
The underlying effective tax rate for the first half increased to 26.0% from 24.2% in the prior year, due to a number of factors including lower benefits from tax settlements and other one-off items. For full year 2024, we raise our guidance for the underlying effective tax rate to around 26%, from around 25% previously. The effective tax rate was 28.6%, up from 26.9% in the prior year.
Joint ventures, associates and other income from non-current investments
Net profit from joint ventures and associates was €138 million, an increase of €20 million compared to 2023, mainly driven by the Pepsi-Lipton JVs. Other income from non-current investments was negative at €(5) million, versus €(10) million in the prior year.
Earnings per share
Underlying earnings per share increased 16.3% to €1.62, including (1.0)% of adverse currency. The increase primarily reflects a strong operational performance and a reduction in the average number of shares as a result of the share buyback programme, which contributed 1.0%. These were partially offset by higher tax and net finance costs. Diluted earnings per share of €1.47 increased by 5.4% versus the prior year that was boosted by profits on disposal.
Restructuring costs
Restructuring costs were €248 million in the first half, up from €184 million in the prior year. For full year 2024, we anticipate restructuring costs of around 1.2% of Group turnover, with the step-up in the second half driven by cost related to the implementation of the productivity programme.
Free cash flow
Free cash flow in the first half of 2024 was €2.2 billion versus €2.5 billion delivered in the first half of 2023. The increase in operating profit was more than offset by a higher seasonal outflow in working capital, a step-up in capital expenditure, and higher income tax paid.
Net debt
Closing net debt was €25.2 billion compared to €23.7 billion as at 31 December 2023. This translated into a net debt / Underlying EBITDA ratio of 2.0x. The increase in net debt was driven by dividends paid, €375 million of the share buyback programme executed during the first half, partially offset by free cash flow delivery.
Pensions
Pension assets net of liabilities were in surplus of €2.7 billion at 30 June 2024 versus a surplus of €2.4 billion at the end of 2023. The increase was primarily driven by strong investment returns in the first half.
Financial implications and impairment risk in Russia
Our Russia business employs approximately 3,000 people in Russia and in the first six months of 2024 the business represented around 1% of the Group’s turnover and net profit. As at 30 June 2024, our Russia business had net assets of around €600 million, including four factories. We continually review our position and still conclude that the containment actions we put in place at the beginning of the war minimise our economic contribution to the Russian state.
We will continue to review and disclose the financial implications from the conflict. While the potential impacts remain uncertain, there remains a risk that our operations in Russia are unable to continue, leading to loss of turnover, profit and a write-down of assets.
Share buyback programme
On 8 February 2024, we announced a share buyback programme of up to €1.5 billion to be completed over 2024. The first tranche of up to €850 million commenced on 17 May. In the first half of 2024, we repurchased 7,315,036 ordinary shares which are held by Unilever as treasury shares. Consideration paid for the repurchase of shares including transaction costs was €375 million which is recorded within other reserves. The first tranche is expected to complete on or before 30 August 2024.

USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
8

Additional commentary on the financial statements - First Half (continued)
Finance and liquidity
In the first six months of 2024, the following notes matured and were repaid:
•March: $500 million 3.25% fixed rate notes
•April: €500 million 0.50% fixed rate notes
•May: $1,000 million 2.60% fixed rate notes
The following notes were issued:
•February: €600 million 3.25% fixed rate notes due 15 February 2032 and €600 million 3.50% fixed rate notes due
15 February 2037
•March: €100 million 3.25% fixed rate notes to be consolidated and form a single series with the €600 million 3.25% fixed rate notes issued in February and due 15 February 2032
•June: $170 million 4.75% fixed rate notes due 27 June 2031
On 30 June 2024, Unilever had undrawn revolving 364-day bilateral credit facilities in aggregate of $5,200 million and €2,600 million with a 364-day term out.
USG, UVG, UPG, UOP, UOM, underlying EPS, constant underlying EPS, underlying effective tax rate, FCF and net debt are non-GAAP measures (see pages 10 to 15)
9

Non-GAAP measures
Certain discussions and analyses set out in this announcement include measures which are not defined by generally accepted accounting principles (GAAP) such as IFRS. We believe this information, along with comparable GAAP measurements, is useful to investors because it provides a basis for measuring our operating performance, ability to retire debt and invest in new business opportunities. Our management uses these financial measures, along with the most directly comparable GAAP financial measures, in evaluating our operating performance and value creation. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP. Wherever appropriate and practical, we provide reconciliations to relevant GAAP measures.
Unilever uses ‘constant rate’, and ‘underlying’ measures primarily for internal performance analysis and targeting purposes. We present certain items, percentages and movements, using constant exchange rates, which exclude the impact of fluctuations in foreign currency exchange rates. We calculate constant currency values by translating both the current and the prior period local currency amounts using the prior year average exchange rates into euro, except for the local currency of entities that operate in hyperinflationary economies. These currencies are translated into euros using the prior year closing exchange rate before the application of IAS 29.
The table below shows exchange rate movements in our key markets.
Half year average rate in 2024Half year average rate in 2023
Brazilian Real (€1 = BRL)5.4785.493
Chinese Yuan (€1 = CNY)7.7327.475
Indian Rupee (€1 = INR)90.00488.860
Indonesia Rupiah (€1 = IDR)17,18016,277
Philippine Peso (€1 = PHP)61.45959.674
UK Pound Sterling (€1 = GBP)0.8550.877
US Dollar (€1 = US $)1.0821.081
Underlying sales growth (USG)
Underlying sales growth (USG) refers to the increase in turnover for the period, excluding any change in turnover resulting from acquisitions, disposals, changes in currency and price growth in excess of 26% in hyperinflationary economies. Inflation of 26% per year compounded over three years is one of the key indicators within IAS 29 to assess whether an economy is deemed to be hyperinflationary. We believe this measure provides valuable additional information on the underlying sales performance of the business and is a key measure used internally. The impact of acquisitions and disposals is excluded from USG for a period of 12 calendar months from the applicable closing date. Turnover from acquired brands that are launched in countries where they were not previously sold is included in USG as such turnover is more attributable to our existing sales and distribution network than the acquisition itself.
The reconciliation of changes in the GAAP measure of turnover to USG is as follows:
(unaudited)Beauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Second Quarter (%)
Turnover growth6.3 0.3 1.8 0.9 2.0 2.2 
Effect of acquisitions1.0 – – – 1.9 0.5 
Effect of disposals(0.8)(4.1)– (0.3)– (1.1)
Effect of currency-related items, of which:(0.6)(1.6)(1.5)(1.5)0.5 (1.0)
Exchange rates changes(2.3)(3.2)(4.9)(3.3)(1.5)(3.1)
Extreme price growth in hyperinflationary markets*1.7 1.6 3.5 1.9 2.1 2.1 
Underlying sales growth6.8 6.4 3.4 2.7 (0.5)3.9 
First Half (%)
Turnover growth5.1 0.6 2.0 1.3 2.8 2.3 
Effect of acquisitions0.9 – – – 1.9 0.5 
Effect of disposals(1.6)(3.4)– (0.4)– (1.2)
Effect of currency-related items, of which:(1.2)(1.4)(1.3)(1.4)0.3 (1.1)
Exchange rates changes(2.7)(3.2)(4.5)(3.1)(1.6)(3.1)
Extreme price growth in hyperinflationary markets*1.6 1.9 3.4 1.7 2.0 2.1 
Underlying sales growth7.1 5.6 3.3 3.2 0.6 4.1 
*Underlying price growth in excess of 26% per year in hyperinflationary economies has been excluded when calculating the underlying sales growth in the tables above, and an equal and opposite amount is shown as extreme price growth in hyperinflationary markets.
10

Non-GAAP measures (continued)
(unaudited)Asia Pacific AfricaThe AmericasEuropeTotal
Second Quarter (%)
Turnover growth0.5 3.9 2.9 2.2 
Effect of acquisitions– 1.5 – 0.5 
Effect of disposals(0.2)(2.5)(0.7)(1.1)
Effect of currency-related items, of which:(2.6)– 0.5 (1.0)
Exchange rates changes(4.2)(3.8)0.5 (3.1)
Extreme price growth in hyperinflationary markets*1.8 3.9 – 2.1 
Underlying sales growth3.4 5.0 3.0 3.9 
First Half (%)
Turnover growth(0.4)4.6 3.8 2.3 
Effect of acquisitions– 1.3 – 0.5 
Effect of disposals(0.2)(2.8)(0.4)(1.2)
Effect of currency-related items, of which:(3.5)0.9 0.7 (1.1)
Exchange rates changes(4.9)(3.0)0.7 (3.1)
Extreme price growth in hyperinflationary markets*1.5 4.1 – 2.1 
Underlying sales growth3.5 5.4 3.5 4.1 
*Underlying price growth in excess of 26% per year in hyperinflationary economies has been excluded when calculating the underlying sales growth in the tables above, and an equal and opposite amount is shown as extreme price growth in hyperinflationary markets.
Underlying price growth (UPG)
Underlying price growth (UPG) is part of USG and means, for the applicable period, the increase in turnover attributable to changes in prices during the period. UPG therefore excludes the impact to USG due to (i) the volume of products sold; and (ii) the composition of products sold during the period. In determining changes in price, we exclude the impact of price growth in excess of 26% per year in hyperinflationary economies as explained in USG above.
Underlying volume growth (UVG)
Underlying volume growth (UVG) is part of USG and means, for the applicable period, the increase in turnover in such period calculated as the sum of (i) the increase in turnover attributable to the volume of products sold; and (ii) the increase in turnover attributable to the composition of products sold during such period. UVG therefore excludes any impact on USG due to changes in prices.
Non-underlying items
Several non-GAAP measures are adjusted to exclude items defined as non-underlying due to their nature and/or frequency of occurrence:
•Non-underlying items within operating profit are: gains or losses on business disposals, acquisition and disposal related costs, restructuring costs, impairments and other items within operating profit classified here due to their nature and frequency.
•Non-underlying items not in operating profit but within net profit are: net monetary gain/(loss) arising from hyperinflationary economies and significant and unusual items in net finance cost, share of profit/(loss) of joint ventures and associates and taxation.
•Non-underlying items are both non-underlying items within operating profit and those non-underlying items not in operating profit but within net profit.
Restructuring costs are charges associated with activities planned by management that significantly change either the scope of the business or the manner in which it is conducted.
11

Non-GAAP measures (continued)
The breakdown of non-underlying items is shown below:
€ millionFirst Half
(unaudited)20242023
Non-underlying items within operating profit before tax(152)308 
Acquisition and disposal-related costs(a)
(58)(52)
Gain on disposal of group companies(b)
155 528 
Restructuring costs(c)
(248)(184)
Impairments(d)
– (1)
Other(1)17 
Tax on non-underlying items within operating profit(51)(111)
Non-underlying items within operating profit after tax(203)197 
Non-underlying items not in operating profit but within net profit before tax(160)(103)
Interest related to the UK tax audit of intangible income and centralised services(3)(5)
Net monetary loss arising from hyperinflationary economies(157)(98)
Tax impact of non-underlying items not in operating profit but within net profit:(4)(80)
Taxes related to the separation of the Tea business4 (6)
Taxes related to the UK tax audit of intangible income and centralised services1 1 
Hyperinflation adjustment for Argentina and Turkey deferred tax(9)(75)
Non-underlying items not in operating profit but within net profit after tax(164)(183)
Non-underlying items after tax(e)
(367)14 
Attributable to:
Non-controlling interests(1)– 
Shareholders’ equity(366)14 
(a) 2024 includes a charge of €36 million relating to the acquisition of Yasso, €11 million relating to the disposal of Elida Beauty, €6 million (2023: €4 million) relating to the disposal of the Tea business and other acquisition and disposal activities.
(b) 2024 includes a gain of €151 million related to the disposal of Elida Beauty. 2023 includes a gain of €497 million related to the disposal of Suave business in North America.
(c) Restructuring costs are comprised of organisational change programmes (including Compass) and various technology and supply chain optimisation projects.
(d) Impairments include write downs of leased land and building assets.
(e) Non-underlying items after tax is calculated as non-underlying items within operating profit after tax plus non-underlying items not in operating profit but within net profit after tax.
Underlying operating profit (UOP) and underlying operating margin (UOM)
Underlying operating profit and underlying operating margin mean operating profit and operating margin before the impact of non-underlying items within operating profit. Underlying operating profit represents our measure of segment profit or loss as it is the primary measure used for making decisions about allocating resources and assessing performance of the segments. The reconciliation of operating profit to underlying operating profit is as follows:
€ millionFirst Half
(unaudited)20242023
Operating profit5,948 5,516 
Non-underlying items within operating profit152 (308)
Underlying operating profit6,100 5,208 
Turnover31,117 30,428 
Operating margin (%)19.1 18.1 
Underlying operating margin (%)19.6 17.1 

12

Non-GAAP measures (continued)
Underlying effective tax rate
The underlying effective tax rate is calculated by dividing taxation excluding the tax impact of non-underlying items by profit before tax excluding the impact of non-underlying items and share of net (profit)/loss of joint ventures and associates. This measure reflects the underlying tax rate in relation to profit before tax excluding non-underlying items before tax and share of net profit/(loss) of joint ventures and associates. Tax impact on non-underlying items within operating profit is the sum of the tax on each non-underlying item, based on the applicable country tax rates and tax treatment. This is shown in the following table:
€ millionFirst Half
(unaudited)20242023
Taxation1,550 1,385 
Tax impact of:
Non-underlying items within operating profit(a)
(51)(111)
Non-underlying items not in operating profit but within net profit(a)
(4)(80)
Taxation before tax impact of non-underlying items1,495 1,194 
Profit before taxation5,566 5,267 
Share of net (profit)/loss of joint ventures and associates(138)(118)
Profit before tax excluding share of net profit/(loss) of joint ventures and associates5,428 5,149 
Non-underlying items within operating profit before tax(a)
152 (308)
Non-underlying items not in operating profit but within net profit before tax160 103 
Profit before tax excluding non-underlying items before tax and share of net profit/(loss) of joint ventures and associates5,740 4,944 
Effective tax rate (%)28.6 26.9 
Underlying effective tax rate (%)26.0 24.2 
(a) See page 12.
Underlying earnings per share
Underlying earnings per share (underlying EPS) is calculated as underlying profit attributable to shareholders’ equity divided by the diluted average number of ordinary shares. In calculating underlying profit attributable to shareholders’ equity, net profit attributable to shareholders’ equity is adjusted to eliminate the post-tax impact of non-underlying items. This measure reflects the underlying earnings for each share unit of the Group. Refer to note 6 for reconciliation of net profit attributable to shareholders’ equity to underlying profit attributable to shareholders' equity.
The reconciliation of net profit attributable to shareholders’ equity to underlying profit attributable to shareholders' equity is as follows:
€ millionFirst Half
(unaudited)20242023
Net profit
4,016 3,882 
Non-controlling interest
(315)(334)
Net profit attributable to shareholders’ equity - used for basic and diluted earnings per share
3,701 3,548 
Post-tax impact of non-underlying items attributable to shareholders’ equity
366 (14)
Underlying profit attributable to shareholders’ equity - used for basic and diluted earnings per share
4,067 3,534 
Adjusted average number of shares (millions of share units)2,511.0 2,536.8 
Diluted EPS (€)
1.47 1.40 
Underlying EPS – diluted (€)1.62 1.39 

13

Non-GAAP measures (continued)
Constant underlying EPS
Constant underlying earnings per share (constant underlying EPS) is calculated as underlying profit attributable to shareholders’ equity at constant exchange rates and excluding the impact of both translational hedges and price growth in excess of 26% per year in hyperinflationary economies divided by the diluted average number of ordinary shares. This measure reflects the underlying earnings for each share unit of the Group in constant exchange rates.
The reconciliation of underlying profit attributable to shareholders’ equity to constant underlying earnings attributable to shareholders’ equity and the calculation of constant underlying EPS is as follows:

€ millionFirst Half
(unaudited)20242023
Underlying profit attributable to shareholders’ equity4,067 3,534 
Impact of translation from current to constant exchange rates and translational hedges75 (104)
Impact of price growth in excess of 26% per year in hyperinflationary economies(159)– 
Constant underlying earnings attributable to shareholders’ equity3,983 3,430 
Diluted average number of share units (millions of units)2,511.0 2,536.8 
Constant underlying EPS (€)1.59 1.35 
Net debt
Net debt is a measure that provides valuable additional information on the summary presentation of the Group’s net financial liabilities and is a measure in common use elsewhere. Net debt is defined as the excess of total financial liabilities, excluding trade payables and other current liabilities, over cash, cash equivalents and other current financial assets, excluding trade and other current receivables, and non-current financial asset derivatives that relate to financial liabilities.
The reconciliation of total financial liabilities to net debt is as follows:

€ million
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
(unaudited)
Total financial liabilities(31,654)(29,622)(30,708)
Current financial liabilities(7,643)(5,087)(6,715)
Non-current financial liabilities(24,011)(24,535)(23,993)
Cash and cash equivalents as per balance sheet4,970 4,159 4,994 
Cash and cash equivalents as per cash flow statement4,854 4,045 4,870 
Add: bank overdrafts deducted therein116 116 124 
Less: cash and cash equivalents held for sale– (2)– 
Other current financial assets1,445 1,731 1,376 
Non-current financial asset derivatives that relate to financial liabilities39 75 31 
Net debt(25,200)(23,657)(24,307)

14

Non-GAAP measures (continued)
Free cash flow (FCF)
Within the Unilever Group, free cash flow (FCF) is defined as cash flow from operating activities, less income taxes paid, net capital expenditure and net interest payments. It does not represent residual cash flows entirely available for discretionary purposes; for example, the repayment of principal amounts borrowed is not deducted from FCF. FCF reflects an additional way of viewing our liquidity that we believe is useful to investors because it represents cash flows that could be used for distribution of dividends, repayment of debt or to fund our strategic initiatives, including acquisitions, if any.
The reconciliation of cash flow from operating activities to FCF is as follows:
€ millionFirst Half
(unaudited)20242023
Cash flow from operating activities4,679 4,377 
Income tax paid(1,315)(1,011)
Net capital expenditure(710)(548)
Net interest paid(502)(364)
Free cash flow2,152 2,454 
Net cash flow (used in)/from investing activities(392)(200)
Net cash flow (used in)/from financing activities(2,154)(2,489)

Other Information
This document represents Unilever’s half-yearly report for the purposes of the Disclosure Guidance and Transparency Rules (DTR) issued by the UK Financial Conduct Authority (DTR 4.2) and the Dutch Act on Financial Supervision, section 5:25d (8)/(9) (Half-yearly financial reports). In this context: (i) the condensed consolidated financial statements can be found on pages 19 to 28; (ii) pages 2 to 15 comprise the interim management report; and (iii) the Directors’ responsibility statement can be found on page 17.

Principal Risk Factors
On pages 71 to 78 of our 2023 Annual Report and Accounts we set out our assessment of the principal risk issues that would face the business under the headings: brand preference; portfolio management; climate change; plastic packaging; customer; talent; supply chain; safe and high quality products; systems and information; business transformation; economic and political instability; treasury and tax; ethical; and legal and regulatory. In our view, the nature and potential impact of such risks remain essentially unchanged as regards our performance over the second half of 2024.

15

Cautionary Statement
This announcement may contain forward-looking statements, including 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, concerning the financial condition, results of operations and businesses of the Unilever Group (the 'Group'). All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Words and terminology such as 'will', 'aim', 'expects', 'anticipates', 'intends', 'looks', 'believes', 'vision', 'ambition', 'target', 'goal', 'plan', 'potential', 'work towards', 'may', 'milestone', 'objectives', 'outlook', 'probably', 'project', 'risk', 'seek', 'continue', 'projected', 'estimate', 'achieve' or the negative of these terms, and other similar expressions of future performance, results, actions or events, and their negatives, are intended to identify such forward-looking statements. Forward-looking statements also include, but are not limited to, statements and information regarding Unilever's acceleration of its Growth Action Plan, Unilever's portfolio optimisation towards global or scalable brands, the capabilities and potential of such brands, the various aspects of the separation of Ice Cream and its future operational model, strategy, growth potential, performance and returns, Unilever's productivity programme, its impacts and cost savings over the next three years and operation dis-synergies from the separation of Ice Cream, the Group's emissions reduction targets and other climate change related matters (including actions, potential impacts and risks associated therewith). Forward-looking statements can be made in writing but also may be made verbally by directors, officers and employees of the Group (including during management presentations) in connection with this announcement. These forward-looking statements are based upon current beliefs, expectations and assumptions regarding anticipated developments and other factors affecting the Group. They are not historical facts, nor are they guarantees of future performance or outcomes. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements.
Because these forward-looking statements involve known and unknown risks and uncertainties, a number of which may be beyond the Group's control, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially from the forward-looking statements expressed in this announcement are: Unilever's ability to successfully separate Ice Cream and realise the anticipated benefits of the separation; Unilever's ability to successfully execute and consummate its productivity programme in line with expected costs to achieve expected savings; Unilever's global brands not meeting consumer preferences; Unilever's ability to innovate and remain competitive; Unilever's investment choices in its portfolio management; the effect of climate change on Unilever's business; Unilever's ability to find sustainable solutions to its plastic packaging; significant changes or deterioration in customer relationships; the recruitment and retention of talented employees; disruptions in Unilever's supply chain and distribution; increases or volatility in the cost of raw materials and commodities; the production of safe and high quality products; secure and reliable IT infrastructure; execution of acquisitions, divestitures and business transformation projects; economic, social and political risks and natural disasters; financial risks; failure to meet high and ethical standards; and managing regulatory, tax and legal matters.
The forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, the Group expressly disclaims any intention, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. New risks and uncertainties arise over time, and it is not possible for us to predict those events or how they may affect us. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Further details of potential risks and uncertainties affecting the Group are described in the Group’s filings with the London Stock Exchange, Euronext Amsterdam and the US Securities and Exchange Commission, including in the Annual Report on Form 20-F 2023 and the Unilever Annual Report and Accounts 2023.

16

Directors' Responsibility Statement
The Directors declare that, to the best of their knowledge:
•these condensed consolidated financial statements, which have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’, as issued by the International Accounting Standard Board and endorsed and adopted by the UK and the EU gives a true and fair view of the assets, liabilities, financial position and profit or loss of Unilever; and
•the interim management report gives a fair review of the information required pursuant to regulations 4.2.7 and 4.2.8 of the Disclosure Guidance and Transparency Rules (DTR) issued by the UK Financial Conduct Authority and section 5:25d (8)/(9) of the Dutch Act on Financial Supervision (Wet op het financieel toezicht).
Unilever’s Directors are listed in the Annual Report and Accounts for 2023.
Details of all current Directors are available on our website at www.unilever.com

By order of the Board


Hein Schumacher                Fernando Fernandez
Chief Executive Officer                 Chief Financial Officer

25 July 2024

Enquiries
Media: Media Relations Team
Investors: Investor Relations Team
UK+44 78 2527 3767lucila.zambrano@unilever.com
investor.relations@unilever.com
or+44 77 7999 9683jonathan.sibun@teneo.com
NL+31 62 191 3705kiran.hofker@unilever.com
or+31 61 500 8293fleur-van.bruggen@unilever.com
After the conference call on 25 July 2024 at 8:00 AM (UK time), the webcast of the presentation will be available at: www.unilever.com/investor-relations/results-and-presentations/latest-results.
This Results Presentation has been submitted to the FCA National Storage Mechanism and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

17



















THIS PAGE INTENTIONALLY LEFT BLANK

18

Consolidated income statement
€ millionFirst Half
(unaudited)20242023Change
Turnover31,117 30,428 2.3 %
Operating profit5,948 5,516 7.8 %
Net finance costs(358)(259)
Pensions and similar obligations35 50 
Finance income217 208 
Finance costs(610)(517)
Net monetary gain/(loss) arising from hyperinflationary economies(157)(98)
Share of net profit/(loss) of joint ventures and associates138 118 
Other income/(loss) from non-current investments and associates(5)(10)
Profit before taxation5,566 5,267 5.7 %
Taxation(1,550)(1,385)
Net profit4,016 3,882 3.5 %
Attributable to:
Non-controlling interests315 334 
Shareholders’ equity3,701 3,548 4.3 %
Earnings per share
Basic earnings per share (euros)1.48 1.41 5.3 %
Diluted earnings per share (euros)1.47 1.40 5.4 %

Consolidated statement of comprehensive income
€ millionFirst Half
(unaudited)20242023
Net profit4,016 3,882 
Other comprehensive income
Items that will not be reclassified to profit or loss, net of tax:
Gains/(losses) on equity instruments measured at fair value through other comprehensive income31 (34)
Remeasurement of defined benefit pension plans201 (47)
Items that may be reclassified subsequently to profit or loss, net of tax:
Gains/(losses) on cash flow hedges58 (22)
Currency retranslation gains/(losses)756 (555)
Total comprehensive income5,062 3,224 
Attributable to:
Non-controlling interests379 284 
Shareholders’ equity4,683 2,940 
19

Consolidated statement of changes in equity
(unaudited)
€ millionCalled
up share
capital		Share
premium
account		Unification
reserve		Other
reserves		Retained
profit		TotalNon-
controlling
interest		Total
equity
First half - 2024
1 January 202488 52,844 (73,364)(8,518)47,052 18,102 2,662 20,764 
Profit or loss for the period– – – – 3,701 3,701 315 4,016 
Other comprehensive income, net of tax:
Gains/(losses) on:
Equity instruments– – – 31 – 31 – 31 
Cash flow hedges– – – 58 – 58 – 58 
Remeasurements of defined benefit pension plans– – – – 200 200 1 201 
Currency retranslation gains/(losses)(d)
– – – 10 683 693 63 756 
Total comprehensive income– – – 99 4,584 4,683 379 5,062 
Dividends on ordinary capital– – – – (2,136)(2,136)– (2,136)
Repurchase of shares(a)
– – – (375)– (375)– (375)
Movements in treasury shares(b)
– – – 25 (100)(75)– (75)
Share-based payment credit(c)
– – – – 164 164 – 164 
Dividends paid to non-controlling interests– – – – – – (354)(354)
Hedging gain/(loss) transferred to non-financial assets– – – 1 – 1 – 1 
Other movements in equity(e)
– – – (59)3 (56)28 (28)
30 June 20248852,844 (73,364)(8,827)49,567 20,308 2,715 23,023 
First half - 2023
1 January 202392 52,844 (73,364)(10,804)50,253 19,021 2,680 21,701 
Profit or loss for the period– – – – 3,548 3,548 334 3,882 
Other comprehensive income, net of tax:
Gains/(losses) on:
Equity instruments– – – (33)– (33)(1)(34)
Cash flow hedges– – – (22)– (22)– (22)
Remeasurements of defined benefit pension plans– – – – (48)(48)1 (47)
Currency retranslation gains/(losses)(d)
– – – (736)231 (505)(50)(555)
Total comprehensive income– – – (791)3,731 2,940 284 3,224 
Dividends on ordinary capital– – – – (2,172)(2,172)– (2,172)
Repurchase of shares(a)
– – – (753)– (753)– (753)
Movements in treasury shares(b)
– – – 69 (68)1 – 1 
Share-based payment credit(c)
– – – – 159 159 – 159 
Dividends paid to non-controlling interests– – – – – – (276)(276)
Hedging loss transferred to non-financial assets– – – 78 – 78 – 78 
Other movements in equity
– – – 5 (22)(17)(24)(41)
30 June 202392 52,844 (73,364)(12,196)51,881 19,257 2,664 21,921 
(a) Repurchase of shares reflects the cost of acquiring ordinary shares as part of the share buyback program announced on 10 February 2022 and 8 February 2024.    
(b) Includes purchases and sales of treasury shares, other than the share buyback programme and the transfer from treasury shares to retained profit of share-settled schemes arising from prior years and differences between purchase and grant price of share awards.
(c) The share-based payment credit relates to the non-cash charge recorded against operating profit in respect of the fair value of share options and awards granted to employees.
(d) 2024 includes a hyperinflation adjustment of €680 million (2023: €247 million) in relation to Argentina and Turkey.
(e) Includes the following items related to the acquisition of K18: €(59) million non-controlling interest purchase option in other reserves and €28 million non-controlling interest recognised on acquisition.
20

Consolidated balance sheet
(unaudited)
€ millionAs at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Non-current assets
Goodwill22,009 21,109 21,299 
Intangible assets19,092 18,357 18,664 
Property, plant and equipment11,098 10,707 10,590 
Pension asset for funded schemes in surplus3,837 3,781 4,244 
Deferred tax assets1,055 1,113 1,084 
Financial assets1,506 1,386 1,220 
Other non-current assets1,014 911 952 
59,611 57,364 58,053 
Current assets
Inventories5,621 5,119 5,668 
Trade and other current receivables7,999 5,775 8,046 
Current tax assets168 427 254 
Cash and cash equivalents4,970 4,159 4,994 
Other financial assets1,445 1,731 1,376 
Assets held for sale18 691 18 
20,221 17,902 20,356 
Total assets79,832 75,266 78,409 
Current liabilities
Financial liabilities7,643 5,087 6,715 
Trade payables and other current liabilities17,209 16,857 17,367 
Current tax liabilities721 851 891 
Provisions557 537 634 
Liabilities held for sale– 175 – 
26,130 23,507 25,607 
Non-current liabilities
Financial liabilities24,011 24,535 23,993 
Non-current tax liabilities494 384 280 
Pensions and post-retirement healthcare liabilities:
Funded schemes in deficit144 351 431 
Unfunded schemes1,002 1,029 1,040 
Provisions581 563 547 
Deferred tax liabilities4,263 3,995 4,410 
Other non-current liabilities184 138 180 
30,679 30,995 30,881 
Total liabilities56,809 54,502 56,488 
Equity
Shareholders’ equity20,308 18,102 19,257 
Non-controlling interests2,715 2,662 2,664 
Total equity23,023 20,764 21,921 
Total liabilities and equity79,832 75,266 78,409 

21

Consolidated cash flow statement
(unaudited)First Half
€ million20242023
Net profit4,016 3,882 
Taxation1,550 1,385 
Share of net (profit)/loss of joint ventures/associates and other (income)/loss from non-current investments and associates(133)(108)
Net monetary (gain)/loss arising from hyperinflationary economies157 98 
Net finance costs358 259 
Operating profit5,948 5,516 
Depreciation, amortisation and impairment794 754 
Changes in working capital(2,127)(1,331)
Inventories(435)100 
Trade and other receivables(2,159)(1,229)
Trade payables and other liabilities467 (202)
Pensions and similar obligations less payments36 (103)
Provisions less payments35 (122)
Elimination of (profits)/losses on disposals(135)(507)
Non-cash charge for share-based compensation164 159 
Other adjustments(36)11 
Cash flow from operating activities4,679 4,377 
Income tax paid(1,315)(1,011)
Net cash flow from operating activities3,364 3,366 
Interest received189 139 
Purchase of intangible assets(98)(92)
Purchase of property, plant and equipment(617)(478)
Disposal of property, plant and equipment5 22 
Acquisition of businesses and investments in joint ventures and associates(797)(67)
Disposal of businesses, joint ventures and associates489 419 
Acquisition of other non-current investments(108)(202)
Disposal of other non-current investments47 37 
Dividends from joint ventures, associates and other non-current investments94 98 
(Purchase)/sale of financial assets404 (76)
Net cash flow (used in)/from investing activities(392)(200)
Dividends paid on ordinary share capital(2,136)(2,202)
Interest paid(691)(503)
Net change in short-term borrowings850 158 
Additional financial liabilities3,016 3,511 
Repayment of financial liabilities(2,297)(2,242)
Capital element of lease rental payments(191)(197)
Repurchase of shares(375)(753)
Other financing activities(330)(261)
Net cash flow (used in)/from financing activities(2,154)(2,489)
Net increase/(decrease) in cash and cash equivalents818 677 
Cash and cash equivalents at the beginning of the period4,045 4,225 
Effect of foreign exchange rate changes(9)(32)
Cash and cash equivalents at the end of the period4,854 4,870 

22

Notes to the condensed consolidated financial statements
(unaudited)

1.Accounting information and policies
These condensed consolidated financial statements are prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board (IASB) and as adopted for use in the UK.
As required by the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the condensed consolidated financial statements have been prepared applying the accounting policies and presentation that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. In preparing these condensed consolidated financial statements, judgements and estimates that affect the application of accounting policies used by management have remained consistent with those applied in the consolidated financial statements for the year ended 31 December 2023.
Management have produced forecasts which have been modelled for different plausible scenarios. These scenarios confirm the Group is able to generate profits and cash in the year ended 31 December 2024 and beyond. As a result, the Directors have a reasonable expectation that the Group has adequate resources to meet its obligations as they fall due for a period of at least 12 months from the date of signing these condensed consolidated financial statements. Accordingly, they continue to adopt the going concern basis in preparing the half year condensed consolidated financial statements.
The condensed consolidated financial statements are shown at current exchange rates with year-on-year changes shown to facilitate comparison. The consolidated income statement on page 19, the consolidated statement of comprehensive income on page 19, the consolidated statement of changes in equity on page 20 and the consolidated cash flow statement on page 22 are translated at exchange rates current in each period. The consolidated balance sheet on page 21 is translated at period-end rates of exchange.
The condensed consolidated financial statements attached do not constitute the full financial statements within the meaning of section 434 of the UK Companies Act 2006. The comparative figures for the financial year ended 31 December 2023 are not Unilever PLC’s statutory accounts for that financial year. The annual financial statements of the Group are prepared in accordance with international financial reporting standards (IFRS) as issued by the International Accounting Standards Board (IASB) and UK adopted international accounting standards and in accordance with the requirements of the UK Companies Act 2006.
Recent accounting developments adopted by the Group
The Group adopted the amendments to IAS 7 and IFRS 7 “Supplier Finance Arrangements” from reporting period beginning 1 January 2024. The amendments introduce additional disclosure requirements for companies that enter supplier finance arrangements. The company will apply these amendments in the 2024 Annual Report.
All other standards or amendments to the standards that have been issued by the IASB and were effective 1 January 2024 were not applicable or material to Unilever.


23

Notes to the condensed consolidated financial statements
(unaudited)
2.Segment information - Business Groups
Second QuarterBeauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Turnover (€ million)
20233,143 3,519 3,057 3,260 2,760 15,739 
20243,343 3,531 3,113 3,289 2,815 16,091 
Change (%)6.3 0.3 1.8 0.9 2.0 2.2 
First HalfBeauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Turnover (€ million)
20236,225 6,911 6,205 6,601 4,486 30,428 
20246,539 6,953 6,328 6,687 4,610 31,117 
Change (%)5.1 0.6 2.0 1.3 2.8 2.3 
Operating profit (€ million)
20231,237 1,691 731 1,213 644 5,516 
20241,269 1,696 963 1,423 597 5,948 
Underlying operating profit (€ million)
20231,179 1,381 763 1,214 671 5,208 
20241,305 1,601 1,031 1,491 672 6,100 
Turnover growth is made up of distinct individual growth components namely underlying sales, currency impact, acquisitions and disposals. Turnover growth is arrived at by multiplying these individual components on a compounded basis as there is a currency impact on each of the other components. Accordingly, turnover growth is more than just the sum of the individual components.
Underlying operating profit represents our measure of segment profit or loss as it is the primary measure used for the purpose of making decisions about allocating resources and assessing performance of segments.

3.Segment information - Geographical area
Second QuarterAsia Pacific AfricaThe AmericasEuropeTotal
Turnover (€ million)
20236,6995,7003,34015,739
20246,7325,9243,43516,091
Change (%)0.5 3.9 2.9 2.2 
First HalfAsia Pacific AfricaThe AmericasEuropeTotal
Turnover (€ million)
202313,421 10,956 6,051 30,428 
202413,370 11,463 6,284 31,117 
Change (%)(0.4)4.6 3.8 2.3 

24

Notes to the condensed consolidated financial statements
(unaudited)
4.Taxation
The effective tax rate for the first half is 28.6% compared with 26.9% in 2023. The tax rate is calculated by dividing the tax charge by pre-tax profit excluding the contribution of joint ventures and associates.
Tax effects of components of other comprehensive income were as follows:
First half
20242023
€ millionBefore taxTax (charge)/creditAfter taxBefore taxTax (charge)/creditAfter tax
Gains/(losses) on:
Equity instruments at fair value through other comprehensive income31 – 31 (34)– (34)
Cash flow hedges63 (5)58 (20)(2)(22)
Remeasurements of defined benefit pension plans242 (41)201 (90)43 (47)
Currency retranslation gains/(losses)772 (16)756 (535)(20)(555)
Other comprehensive income1,108 (62)1,046 (679)21 (658)

5.Earnings per share
The earnings per share calculations are based on the average number of share units representing the ordinary shares of PLC in issue during the period, less the average number of shares held as treasury shares.
In calculating diluted earnings per share, a number of adjustments are made to the number of shares, principally the exercise of share plans by employees.
Earnings per share for total operations for the six months were calculated as follows:
First Half
20242023
EPS – Basic
Net profit attributable to shareholders’ equity (€ million)3,7013,548
Average number of shares (millions of share units)2,499.92,523.9
EPS – basic (€)1.481.41
EPS – Diluted
Net profit attributable to shareholders’ equity (€ million)3,7013,548
Adjusted average number of shares (millions of share units)2,511.02,536.8
EPS – diluted (€)1.471.40
During the period the following movements in shares have taken place:
Millions
Number of shares at 31 December 2023 (net of treasury shares)2,499.0 
Shares repurchased under the share buyback programme(7.3)
Net movements in shares under incentive schemes3.7 
Number of shares at 30 June 2024 (net of treasury shares)2,495.4 

25

Notes to the condensed consolidated financial statements
(unaudited)
6.Acquisitions and disposals
In the first half of 2024, the Group completed the following business acquisitions and disposals:
Deal completion dateAcquired/disposed business
1 February 2024
Acquired 91.88% of K18, a U.S. based premium hair care brand. The acquisition complements Unilever’s existing Beauty and Wellbeing portfolio, with a range of high-quality, hair care products.
1 June 2024
Sold Elida Beauty to Yellow Wood Partners LLC. Elida Beauty comprises more than 20 beauty and personal care brands, such as Q-Tips, Caress, Timotei and TIGI.
On 1 June 2024, Unilever completed the disposal of the Elida Beauty business to Yellow Wood Partners LLC for consideration of €588 million. Profit on this disposal is €151 million, recognised as a non-underlying item.
In July we announced agreements to sell our water purification businesses Pureit, to A.O. Smith, and stake in Qinyuan Group, to Yong Chao Venture Capital Co., Ltd. The deals are expected to complete in the second half of the year.
7.Share buyback
On 8 February 2024, Unilever PLC announced a programme to buy back shares with an aggregate market value equivalent of up to €1.5 billion, to be completed during 2024. On 17 May 2024, Unilever announced the commencement of the first tranche of the buyback programme (the “First Tranche”) for an aggregate market value equivalent of up to €850 million. As at 30 June 2024, 7,315,036 shares had been purchased for €375 million, which will be held as Treasury stock until cancellation.
8.Financial instruments
The Group’s Treasury function aims to protect the Group’s financial investments, while maximising returns. The fair value of financial assets is the same as the carrying amount for 2024 and 2023. The Group’s cash resources and
other financial assets are shown below.
30 June 2024
31 December 2023
30 June 2023
CurrentNon-currentTotalCurrentNon-currentTotalCurrentNon-currentTotal
Cash and cash equivalents
Cash at bank and in hand3,601 – 3,601 2,862 – 2,862 2,790 – 2,790 
Short-term deposits(a)
981 – 981 1,181 – 1,181 1,804 – 1,804 
Other cash equivalents(b)
388 – 388 116 – 116 400 – 400 
4,970 – 4,970 4,159 – 4,159 4,994 – 4,994 
Other financial assets
Financial assets at amortised cost(c)
835 560 1,395 961 454 1,415 727 352 1,079 
Financial assets at fair value through other comprehensive income(d)
61 525 586 151 458 609 – 438 438 
Financial assets at fair value through profit or loss:
  Derivatives79 39 118 37 75 112 36 31 67 
  Other(e)
470 382 852 582 399 981 613 399 1,012 
1,445 1,506 2,951 1,731 1,386 3,117 1,376 1,220 2,596 
Total financial assets(f)
6,415 1,506 7,921 5,890 1,386 7,276 6,370 1,220 7,590 
(a) Short-term deposits typically have maturity of up to 3 months.
(b) Other cash equivalents include investments in overnight funds and marketable securities.
(c) Current financial assets at amortised cost include short term deposits with banks with maturities longer than three months excluding deposits which are part of a recognised cash management process and loans to joint venture entities. Non-current financial assets at amortised cost include judicial deposits of €212 million (31 December 2023: €227 million; 30 June 2023: €228 million).
(d) Included within non-current financial assets at fair value through other comprehensive income are equity investments.
(e) Other financial assets at fair value through profit or loss include money market funds, marketable securities, other capital market instruments
and investments in companies and financial institutions in North America, North Asia, South Asia and Europe.
(f) Financial assets exclude trade and other current receivables.
26

Notes to the condensed consolidated financial statements
(unaudited)
8.Financial instruments (continued)
The Group is exposed to the risks of changes in fair value of its financial assets and liabilities. The following tables summarise the fair values and carrying amounts of financial instruments and the fair value calculations by category.
€ millionFair valueCarrying amount
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Financial assets
Cash and cash equivalents4,970 4,159 4,994 4,970 4,159 4,994 
Financial assets at amortised cost1,395 1,415 1,079 1,395 1,415 1,079 
Financial assets at fair value through other comprehensive income586 609 438 586 609 438 
Financial assets at fair value through profit and loss:
Derivatives118 112 67 118 112 67 
Other852 981 1,012 852 981 1,012 
7,921 7,276 7,590 7,921 7,276 7,590 
Financial liabilities
Bank loans and overdrafts(460)(506)(606)(460)(506)(606)
Bonds and other loans(27,836)(26,112)(26,265)(28,729)(26,692)(27,599)
Lease liabilities(1,358)(1,395)(1,428)(1,358)(1,395)(1,428)
Derivatives(537)(494)(618)(537)(494)(618)
Other financial liabilities(570)(535)(457)(570)(535)(457)
(30,761)(29,042)(29,374)(31,654)(29,622)(30,708)

€ million
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Level 1Level 2Level 3Level 1Level 2Level 3Level 1Level 2Level 3
Assets at fair value
Financial assets at fair value through other comprehensive income70 4 512 163 4 442 14 3 421 
Financial assets at fair value through profit or loss:
Derivatives(a)
– 192 – – 149 – – 142 – 
Other470 – 382 582 – 399 613 – 399 
Liabilities at fair value
Derivatives(b)
– (586)– – (559)– – (718)– 
Contingent consideration– – (8)– – (157)– – (123)
(a) Includes €74 million (31 December 2023: €37 million; 30 June 2023: €75 million) derivatives, reported within trade receivables, that hedge trading activities.
(b) Includes €(49) million (31 December 2023: €(65) million; 30 June 2023: €(100) million) derivatives, reported within trade creditors, that hedge trading activities.
There were no significant changes in classification of fair value of financial assets and financial liabilities since
31 December 2023. There were also no significant movements between the fair value hierarchy classifications since 31 December 2023.
The fair value of trade receivables and payables is considered to be equal to the carrying amount of these items due to their short-term nature. The fair value of financial assets and financial liabilities (excluding listed bonds) is considered to be same as the carrying amount for 2024 and 2023.
Calculation of fair values
The fair values of the financial assets and liabilities are defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Methods and assumptions used to estimate the fair values are consistent with those used in the year ended 31 December 2023.

27

Notes to the condensed consolidated financial statements
(unaudited)
9.Dividends
The Board has declared a quarterly interim dividend for Q2 2024 of £0.3696 per Unilever PLC ordinary share or €0.4396 per Unilever PLC ordinary share at the applicable exchange rate issued by WM/Reuters on 23 July 2024.
The following amounts will be paid in respect of this quarterly interim dividend on the relevant payment date:
Per Unilever PLC ordinary share (traded on the London Stock Exchange):£0.3696
Per Unilever PLC ordinary share (traded on Euronext in Amsterdam):€0.4396
Per Unilever PLC American Depositary Receipt:US$0.4773
The euro and US dollar amounts above have been determined using the applicable exchange rates issued by WM/Reuters on 23 July 2024.
US dollar cheques for the quarterly interim dividend will be mailed on 6 September 2024 to holders of record at the close of business on 9 August 2024.
The quarterly dividend calendar for the remainder of 2024 will be as follows:

Announcement DateEx-Dividend DateRecord DatePayment Date
Q2 2024 Dividend25 July 202408 August 202409 August 202406 September 2024
Q3 2024 Dividend24 October 202407 November 202408 November 202406 December 2024

10.Events after the balance sheet date
There are no material post balance sheet events other than those mentioned elsewhere in this report.

28
v3.24.2
Cover page
 6 Months Ended
Jun. 30, 2024
Cover [Abstract]  
Document Type 6-K
Entity Registrant Name UNILEVER PLC
Amendment Flag false
Entity Central Index Key 0000217410
Current Fiscal Year End Date --12-31
Document Period End Date Jun. 30, 2024
Document Fiscal Year Focus 2024
Document Fiscal Period Focus Q2
v3.24.2
Consolidated income statement - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Profit or loss [abstract]    
Turnover € 31,117 € 30,428
Operating profit 5,948 5,516
Net finance costs (358) (259)
Pensions and similar obligations 35 50
Finance income 217 208
Finance costs (610) (517)
Net monetary gain/(loss) arising from hyperinflationary economies (157) (98)
Share of net profit/(loss) of joint ventures and associates 138 118
Other income/(loss) from non-current investments and associates (5) (10)
Profit before taxation 5,566 5,267
Taxation (1,550) (1,385)
Net profit 4,016 3,882
Attributable to:    
Non-controlling interests 315 334
Shareholders’ equity € 3,701 € 3,548
Earnings per share    
Basic earnings per share (in euros per share) € 1.48 € 1.41
Diluted earnings per share (in euros per share) € 1.47 € 1.40
v3.24.2
Consolidated statement of comprehensive income - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Statement of comprehensive income [abstract]    
Net profit € 4,016 € 3,882
Items that will not be reclassified to profit or loss, net of tax:    
Gains/(losses) on equity instruments measured at fair value through other comprehensive income 31 (34)
Remeasurement of defined benefit pension plans 201 (47)
Items that may be reclassified subsequently to profit or loss, net of tax:    
Gains/(losses) on cash flow hedges 58 (22)
Currency retranslation gains/(losses) [1] 756 (555)
Total comprehensive income 5,062 3,224
Attributable to:    
Non-controlling interests 379 284
Shareholders’ equity € 4,683 € 2,940
[1] 2024 includes a hyperinflation adjustment of €680 million (2023: €247 million) in relation to Argentina and Turkey.
v3.24.2
Consolidated statement of changes in equity - EUR (€)
€ in Millions
Total
Total
Called up share capital
Share premium account
Unification reserve
Other reserves
Retained profit
Non- controlling interest
Equity at beginning of period at Dec. 31, 2022 € 21,701 € 19,021 € 92 € 52,844 € (73,364) € (10,804) € 50,253 € 2,680
Profit or loss for the period 3,882 3,548         3,548 334
Gains/(losses) on:                
Equity instruments (34) (33)       (33)   (1)
Cash flow hedges (22) (22)       (22)    
Remeasurement of defined benefit pension plans (47) (48)         (48) 1
Currency retranslation gains/(losses) [1] (555) (505)       (736) 231 (50)
Total comprehensive income 3,224 2,940       (791) 3,731 284
Dividends on ordinary capital (2,172) (2,172)         (2,172)  
Repurchase of shares [2] (753) (753)       (753)    
Movements in treasury shares [3] 1 1       69 (68)  
Share-based payment credit [4] 159 159         159  
Dividends paid to non-controlling interests (276)             (276)
Hedging gain/(loss) transferred to non-financial assets 78 78       78    
Other movements in equity(e) (41) (17)       5 (22) (24)
Equity at end of period at Jun. 30, 2023 21,921 19,257 92 52,844 (73,364) (12,196) 51,881 2,664
Equity at beginning of period at Dec. 31, 2023 20,764 18,102 88 52,844 (73,364) (8,518) 47,052 2,662
Profit or loss for the period 4,016 3,701         3,701 315
Gains/(losses) on:                
Equity instruments 31 31       31    
Cash flow hedges 58 58       58    
Remeasurement of defined benefit pension plans 201 200         200 1
Currency retranslation gains/(losses) [1] 756 693       10 683 63
Total comprehensive income 5,062 4,683       99 4,584 379
Dividends on ordinary capital (2,136) (2,136)         (2,136)  
Repurchase of shares [2] (375) (375)       (375)    
Movements in treasury shares [3] (75) (75)       25 (100)  
Share-based payment credit [4] 164 164         164  
Dividends paid to non-controlling interests (354)             (354)
Hedging gain/(loss) transferred to non-financial assets 1 1       1    
Other movements in equity(e) [5] (28) (56)       (59) 3 28
Equity at end of period at Jun. 30, 2024 € 23,023 € 20,308 € 88 € 52,844 € (73,364) € (8,827) € 49,567 € 2,715
[1] 2024 includes a hyperinflation adjustment of €680 million (2023: €247 million) in relation to Argentina and Turkey.
[2] Repurchase of shares reflects the cost of acquiring ordinary shares as part of the share buyback program announced on 10 February 2022 and 8 February 2024.
[3] Includes purchases and sales of treasury shares, other than the share buyback programme and the transfer from treasury shares to retained profit of share-settled schemes arising from prior years and differences between purchase and grant price of share awards.
[4] The share-based payment credit relates to the non-cash charge recorded against operating profit in respect of the fair value of share options and awards granted to employees.
[5] Includes the following items related to the acquisition of K18: €(59) million non-controlling interest purchase option in other reserves and €28 million non-controlling interest recognised on acquisition.
v3.24.2
Consolidated statement of changes in equity (Parenthetical) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Hyperinflation adjustment € 680 € 247
Other reserves    
Increase (decrease) through acquisition of subsidiary, equity (59)  
Non- controlling interest    
Increase (decrease) through acquisition of subsidiary, equity € 28  
v3.24.2
Consolidated balance sheet - EUR (€)
€ in Millions
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Non-current assets      
Goodwill € 22,009 € 21,109 € 21,299
Intangible assets 19,092 18,357 18,664
Property, plant and equipment 11,098 10,707 10,590
Pension asset for funded schemes in surplus 3,837 3,781 4,244
Deferred tax assets 1,055 1,113 1,084
Financial assets 1,506 1,386 1,220
Other non-current assets 1,014 911 952
Total non-current assets 59,611 57,364 58,053
Current assets      
Inventories 5,621 5,119 5,668
Trade and other current receivables 7,999 5,775 8,046
Current tax assets 168 427 254
Cash and cash equivalents 4,970 4,159 4,994
Other financial assets 1,445 1,731 1,376
Assets held for sale 18 691 18
Total current assets 20,221 17,902 20,356
Total assets 79,832 75,266 78,409
Current liabilities      
Financial liabilities 7,643 5,087 6,715
Trade payables and other current liabilities 17,209 16,857 17,367
Current tax liabilities 721 851 891
Provisions 557 537 634
Liabilities held for sale 0 175 0
Total current liabilities 26,130 23,507 25,607
Non-current liabilities      
Financial liabilities 24,011 24,535 23,993
Non-current tax liabilities 494 384 280
Pensions and post-retirement healthcare liabilities:      
Funded schemes in deficit 144 351 431
Unfunded schemes 1,002 1,029 1,040
Provisions 581 563 547
Deferred tax liabilities 4,263 3,995 4,410
Other non-current liabilities 184 138 180
Total non current liabilities 30,679 30,995 30,881
Total liabilities 56,809 54,502 56,488
Equity      
Shareholders’ equity 20,308 18,102 19,257
Non-controlling interests 2,715 2,662 2,664
Total equity 23,023 20,764 21,921
Total liabilities and equity € 79,832 € 75,266 € 78,409
v3.24.2
Consolidated cash flow statement - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from (used in) operating activities [abstract]    
Net profit € 4,016 € 3,882
Taxation 1,550 1,385
Share of net (profit)/loss of joint ventures/associates and other (income)/loss from non-current investments and associates (133) (108)
Net monetary (gain)/loss arising from hyperinflationary economies 157 98
Net finance costs 358 259
Operating profit 5,948 5,516
Depreciation, amortisation and impairment 794 754
Changes in working capital (2,127) (1,331)
Inventories (435) 100
Trade and other receivables (2,159) (1,229)
Trade payables and other liabilities 467 (202)
Pensions and similar obligations less payments 36 (103)
Provisions less payments 35 (122)
Elimination of (profits)/losses on disposals (135) (507)
Non-cash charge for share-based compensation 164 159
Other adjustments (36) 11
Cash flow from operating activities 4,679 4,377
Income tax paid (1,315) (1,011)
Net cash flow from operating activities 3,364 3,366
Cash flows from (used in) investing activities [abstract]    
Interest received 189 139
Purchase of intangible assets (98) (92)
Purchase of property, plant and equipment (617) (478)
Disposal of property, plant and equipment 5 22
Acquisition of businesses and investments in joint ventures and associates (797) (67)
Disposal of businesses, joint ventures and associates 489 419
Acquisition of other non-current investments (108) (202)
Disposal of other non-current investments 47 37
Dividends from joint ventures, associates and other non-current investments 94 98
(Purchase)/sale of financial assets 404 (76)
Net cash flow (used in)/from investing activities (392) (200)
Cash flows from (used in) financing activities [abstract]    
Dividends paid on ordinary share capital (2,136) (2,202)
Interest paid (691) (503)
Net change in short-term borrowings 850 158
Additional financial liabilities 3,016 3,511
Repayment of financial liabilities (2,297) (2,242)
Capital element of lease rental payments (191) (197)
Repurchase of shares (375) (753)
Other financing activities (330) (261)
Net cash flow (used in)/from financing activities (2,154) (2,489)
Net increase/(decrease) in cash and cash equivalents 818 677
Cash and cash equivalents at the beginning of the period 4,045 4,225
Effect of foreign exchange rate changes (9) (32)
Cash and cash equivalents at the end of the period € 4,854 € 4,870
v3.24.2
Accounting information and policies
 6 Months Ended
Jun. 30, 2024
Disclosure Of Summary Of Significant Accounting Policies [Abstract]  
Accounting information and policies
1.Accounting information and policies
These condensed consolidated financial statements are prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board (IASB) and as adopted for use in the UK.
As required by the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the condensed consolidated financial statements have been prepared applying the accounting policies and presentation that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. In preparing these condensed consolidated financial statements, judgements and estimates that affect the application of accounting policies used by management have remained consistent with those applied in the consolidated financial statements for the year ended 31 December 2023.
Management have produced forecasts which have been modelled for different plausible scenarios. These scenarios confirm the Group is able to generate profits and cash in the year ended 31 December 2024 and beyond. As a result, the Directors have a reasonable expectation that the Group has adequate resources to meet its obligations as they fall due for a period of at least 12 months from the date of signing these condensed consolidated financial statements. Accordingly, they continue to adopt the going concern basis in preparing the half year condensed consolidated financial statements.
The condensed consolidated financial statements are shown at current exchange rates with year-on-year changes shown to facilitate comparison. The consolidated income statement on page 19, the consolidated statement of comprehensive income on page 19, the consolidated statement of changes in equity on page 20 and the consolidated cash flow statement on page 22 are translated at exchange rates current in each period. The consolidated balance sheet on page 21 is translated at period-end rates of exchange.
The condensed consolidated financial statements attached do not constitute the full financial statements within the meaning of section 434 of the UK Companies Act 2006. The comparative figures for the financial year ended 31 December 2023 are not Unilever PLC’s statutory accounts for that financial year. The annual financial statements of the Group are prepared in accordance with international financial reporting standards (IFRS) as issued by the International Accounting Standards Board (IASB) and UK adopted international accounting standards and in accordance with the requirements of the UK Companies Act 2006.
Recent accounting developments adopted by the Group
The Group adopted the amendments to IAS 7 and IFRS 7 “Supplier Finance Arrangements” from reporting period beginning 1 January 2024. The amendments introduce additional disclosure requirements for companies that enter supplier finance arrangements. The company will apply these amendments in the 2024 Annual Report.
All other standards or amendments to the standards that have been issued by the IASB and were effective 1 January 2024 were not applicable or material to Unilever.
v3.24.2
Segment information - Business Groups
 6 Months Ended
Jun. 30, 2024
Disclosure of operating segments [abstract]  
Segment information - Business Groups
2.Segment information - Business Groups
Second QuarterBeauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Turnover (€ million)
20233,143 3,519 3,057 3,260 2,760 15,739 
20243,343 3,531 3,113 3,289 2,815 16,091 
Change (%)6.3 0.3 1.8 0.9 2.0 2.2 
First HalfBeauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Turnover (€ million)
20236,225 6,911 6,205 6,601 4,486 30,428 
20246,539 6,953 6,328 6,687 4,610 31,117 
Change (%)5.1 0.6 2.0 1.3 2.8 2.3 
Operating profit (€ million)
20231,237 1,691 731 1,213 644 5,516 
20241,269 1,696 963 1,423 597 5,948 
Underlying operating profit (€ million)
20231,179 1,381 763 1,214 671 5,208 
20241,305 1,601 1,031 1,491 672 6,100 
Turnover growth is made up of distinct individual growth components namely underlying sales, currency impact, acquisitions and disposals. Turnover growth is arrived at by multiplying these individual components on a compounded basis as there is a currency impact on each of the other components. Accordingly, turnover growth is more than just the sum of the individual components.
Underlying operating profit represents our measure of segment profit or loss as it is the primary measure used for the purpose of making decisions about allocating resources and assessing performance of segments.
v3.24.2
Segment information - Geographical area
 6 Months Ended
Jun. 30, 2024
Disclosure of operating segments [abstract]  
Segment information - Geographical area
3.Segment information - Geographical area
Second QuarterAsia Pacific AfricaThe AmericasEuropeTotal
Turnover (€ million)
20236,6995,7003,34015,739
20246,7325,9243,43516,091
Change (%)0.5 3.9 2.9 2.2 
First HalfAsia Pacific AfricaThe AmericasEuropeTotal
Turnover (€ million)
202313,421 10,956 6,051 30,428 
202413,370 11,463 6,284 31,117 
Change (%)(0.4)4.6 3.8 2.3 
v3.24.2
Taxation
 6 Months Ended
Jun. 30, 2024
Income taxes paid (refund) [abstract]  
Taxation
4.Taxation
The effective tax rate for the first half is 28.6% compared with 26.9% in 2023. The tax rate is calculated by dividing the tax charge by pre-tax profit excluding the contribution of joint ventures and associates.
Tax effects of components of other comprehensive income were as follows:
First half
20242023
€ millionBefore taxTax (charge)/creditAfter taxBefore taxTax (charge)/creditAfter tax
Gains/(losses) on:
Equity instruments at fair value through other comprehensive income31 – 31 (34)– (34)
Cash flow hedges63 (5)58 (20)(2)(22)
Remeasurements of defined benefit pension plans242 (41)201 (90)43 (47)
Currency retranslation gains/(losses)772 (16)756 (535)(20)(555)
Other comprehensive income1,108 (62)1,046 (679)21 (658)
v3.24.2
Earnings per share
 6 Months Ended
Jun. 30, 2024
Earnings per share [abstract]  
Earnings per share
5.Earnings per share
The earnings per share calculations are based on the average number of share units representing the ordinary shares of PLC in issue during the period, less the average number of shares held as treasury shares.
In calculating diluted earnings per share, a number of adjustments are made to the number of shares, principally the exercise of share plans by employees.
Earnings per share for total operations for the six months were calculated as follows:
First Half
20242023
EPS – Basic
Net profit attributable to shareholders’ equity (€ million)3,7013,548
Average number of shares (millions of share units)2,499.92,523.9
EPS – basic (€)1.481.41
EPS – Diluted
Net profit attributable to shareholders’ equity (€ million)3,7013,548
Adjusted average number of shares (millions of share units)2,511.02,536.8
EPS – diluted (€)1.471.40
During the period the following movements in shares have taken place:
Millions
Number of shares at 31 December 2023 (net of treasury shares)2,499.0 
Shares repurchased under the share buyback programme(7.3)
Net movements in shares under incentive schemes3.7 
Number of shares at 30 June 2024 (net of treasury shares)2,495.4 
v3.24.2
Acquisitions and disposals
 6 Months Ended
Jun. 30, 2024
Disclosure of detailed information about business combination [abstract]  
Acquisitions and disposals
6.Acquisitions and disposals
In the first half of 2024, the Group completed the following business acquisitions and disposals:
Deal completion dateAcquired/disposed business
1 February 2024
Acquired 91.88% of K18, a U.S. based premium hair care brand. The acquisition complements Unilever’s existing Beauty and Wellbeing portfolio, with a range of high-quality, hair care products.
1 June 2024
Sold Elida Beauty to Yellow Wood Partners LLC. Elida Beauty comprises more than 20 beauty and personal care brands, such as Q-Tips, Caress, Timotei and TIGI.
On 1 June 2024, Unilever completed the disposal of the Elida Beauty business to Yellow Wood Partners LLC for consideration of €588 million. Profit on this disposal is €151 million, recognised as a non-underlying item.
In July we announced agreements to sell our water purification businesses Pureit, to A.O. Smith, and stake in Qinyuan Group, to Yong Chao Venture Capital Co., Ltd. The deals are expected to complete in the second half of the year.
v3.24.2
Share buyback
 6 Months Ended
Jun. 30, 2024
Share Buyback [Abstract]  
Share buyback
7.Share buyback
On 8 February 2024, Unilever PLC announced a programme to buy back shares with an aggregate market value equivalent of up to €1.5 billion, to be completed during 2024. On 17 May 2024, Unilever announced the commencement of the first tranche of the buyback programme (the “First Tranche”) for an aggregate market value equivalent of up to €850 million. As at 30 June 2024, 7,315,036 shares had been purchased for €375 million, which will be held as Treasury stock until cancellation.
v3.24.2
Financial instruments
 6 Months Ended
Jun. 30, 2024
Disclosure of detailed information about financial instruments [abstract]  
Financial instruments
8.Financial instruments
The Group’s Treasury function aims to protect the Group’s financial investments, while maximising returns. The fair value of financial assets is the same as the carrying amount for 2024 and 2023. The Group’s cash resources and
other financial assets are shown below.
30 June 2024
31 December 2023
30 June 2023
CurrentNon-currentTotalCurrentNon-currentTotalCurrentNon-currentTotal
Cash and cash equivalents
Cash at bank and in hand3,601 – 3,601 2,862 – 2,862 2,790 – 2,790 
Short-term deposits(a)
981 – 981 1,181 – 1,181 1,804 – 1,804 
Other cash equivalents(b)
388 – 388 116 – 116 400 – 400 
4,970 – 4,970 4,159 – 4,159 4,994 – 4,994 
Other financial assets
Financial assets at amortised cost(c)
835 560 1,395 961 454 1,415 727 352 1,079 
Financial assets at fair value through other comprehensive income(d)
61 525 586 151 458 609 – 438 438 
Financial assets at fair value through profit or loss:
  Derivatives79 39 118 37 75 112 36 31 67 
  Other(e)
470 382 852 582 399 981 613 399 1,012 
1,445 1,506 2,951 1,731 1,386 3,117 1,376 1,220 2,596 
Total financial assets(f)
6,415 1,506 7,921 5,890 1,386 7,276 6,370 1,220 7,590 
(a) Short-term deposits typically have maturity of up to 3 months.
(b) Other cash equivalents include investments in overnight funds and marketable securities.
(c) Current financial assets at amortised cost include short term deposits with banks with maturities longer than three months excluding deposits which are part of a recognised cash management process and loans to joint venture entities. Non-current financial assets at amortised cost include judicial deposits of €212 million (31 December 2023: €227 million; 30 June 2023: €228 million).
(d) Included within non-current financial assets at fair value through other comprehensive income are equity investments.
(e) Other financial assets at fair value through profit or loss include money market funds, marketable securities, other capital market instruments
and investments in companies and financial institutions in North America, North Asia, South Asia and Europe.
(f) Financial assets exclude trade and other current receivables.
Notes to the condensed consolidated financial statements
(unaudited)
8.Financial instruments (continued)
The Group is exposed to the risks of changes in fair value of its financial assets and liabilities. The following tables summarise the fair values and carrying amounts of financial instruments and the fair value calculations by category.
€ millionFair valueCarrying amount
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Financial assets
Cash and cash equivalents4,970 4,159 4,994 4,970 4,159 4,994 
Financial assets at amortised cost1,395 1,415 1,079 1,395 1,415 1,079 
Financial assets at fair value through other comprehensive income586 609 438 586 609 438 
Financial assets at fair value through profit and loss:
Derivatives118 112 67 118 112 67 
Other852 981 1,012 852 981 1,012 
7,921 7,276 7,590 7,921 7,276 7,590 
Financial liabilities
Bank loans and overdrafts(460)(506)(606)(460)(506)(606)
Bonds and other loans(27,836)(26,112)(26,265)(28,729)(26,692)(27,599)
Lease liabilities(1,358)(1,395)(1,428)(1,358)(1,395)(1,428)
Derivatives(537)(494)(618)(537)(494)(618)
Other financial liabilities(570)(535)(457)(570)(535)(457)
(30,761)(29,042)(29,374)(31,654)(29,622)(30,708)

€ million
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Level 1Level 2Level 3Level 1Level 2Level 3Level 1Level 2Level 3
Assets at fair value
Financial assets at fair value through other comprehensive income70 4 512 163 4 442 14 3 421 
Financial assets at fair value through profit or loss:
Derivatives(a)
– 192 – – 149 – – 142 – 
Other470 – 382 582 – 399 613 – 399 
Liabilities at fair value
Derivatives(b)
– (586)– – (559)– – (718)– 
Contingent consideration– – (8)– – (157)– – (123)
(a) Includes €74 million (31 December 2023: €37 million; 30 June 2023: €75 million) derivatives, reported within trade receivables, that hedge trading activities.
(b) Includes €(49) million (31 December 2023: €(65) million; 30 June 2023: €(100) million) derivatives, reported within trade creditors, that hedge trading activities.
There were no significant changes in classification of fair value of financial assets and financial liabilities since
31 December 2023. There were also no significant movements between the fair value hierarchy classifications since 31 December 2023.
The fair value of trade receivables and payables is considered to be equal to the carrying amount of these items due to their short-term nature. The fair value of financial assets and financial liabilities (excluding listed bonds) is considered to be same as the carrying amount for 2024 and 2023.
Calculation of fair values
The fair values of the financial assets and liabilities are defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Methods and assumptions used to estimate the fair values are consistent with those used in the year ended 31 December 2023.
v3.24.2
Dividends
 6 Months Ended
Jun. 30, 2024
Dividends [Abstract]  
Dividends
9.Dividends
The Board has declared a quarterly interim dividend for Q2 2024 of £0.3696 per Unilever PLC ordinary share or €0.4396 per Unilever PLC ordinary share at the applicable exchange rate issued by WM/Reuters on 23 July 2024.
The following amounts will be paid in respect of this quarterly interim dividend on the relevant payment date:
Per Unilever PLC ordinary share (traded on the London Stock Exchange):£0.3696
Per Unilever PLC ordinary share (traded on Euronext in Amsterdam):€0.4396
Per Unilever PLC American Depositary Receipt:US$0.4773
The euro and US dollar amounts above have been determined using the applicable exchange rates issued by WM/Reuters on 23 July 2024.
US dollar cheques for the quarterly interim dividend will be mailed on 6 September 2024 to holders of record at the close of business on 9 August 2024.
The quarterly dividend calendar for the remainder of 2024 will be as follows:

Announcement DateEx-Dividend DateRecord DatePayment Date
Q2 2024 Dividend25 July 202408 August 202409 August 202406 September 2024
Q3 2024 Dividend24 October 202407 November 202408 November 202406 December 2024
v3.24.2
Events after the balance sheet date
 6 Months Ended
Jun. 30, 2024
Disclosure of non-adjusting events after reporting period [abstract]  
Events after the balance sheet date
10.Events after the balance sheet date
There are no material post balance sheet events other than those mentioned elsewhere in this report.
v3.24.2
Accounting information and policies (Policies)
 6 Months Ended
Jun. 30, 2024
Disclosure Of Summary Of Significant Accounting Policies [Abstract]  
Basis of preparation
These condensed consolidated financial statements are prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board (IASB) and as adopted for use in the UK.
As required by the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the condensed consolidated financial statements have been prepared applying the accounting policies and presentation that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. In preparing these condensed consolidated financial statements, judgements and estimates that affect the application of accounting policies used by management have remained consistent with those applied in the consolidated financial statements for the year ended 31 December 2023.
Management have produced forecasts which have been modelled for different plausible scenarios. These scenarios confirm the Group is able to generate profits and cash in the year ended 31 December 2024 and beyond. As a result, the Directors have a reasonable expectation that the Group has adequate resources to meet its obligations as they fall due for a period of at least 12 months from the date of signing these condensed consolidated financial statements. Accordingly, they continue to adopt the going concern basis in preparing the half year condensed consolidated financial statements.
The condensed consolidated financial statements are shown at current exchange rates with year-on-year changes shown to facilitate comparison. The consolidated income statement on page 19, the consolidated statement of comprehensive income on page 19, the consolidated statement of changes in equity on page 20 and the consolidated cash flow statement on page 22 are translated at exchange rates current in each period. The consolidated balance sheet on page 21 is translated at period-end rates of exchange.
The condensed consolidated financial statements attached do not constitute the full financial statements within the meaning of section 434 of the UK Companies Act 2006. The comparative figures for the financial year ended 31 December 2023 are not Unilever PLC’s statutory accounts for that financial year. The annual financial statements of the Group are prepared in accordance with international financial reporting standards (IFRS) as issued by the International Accounting Standards Board (IASB) and UK adopted international accounting standards and in accordance with the requirements of the UK Companies Act 2006.
New acounting standards
Recent accounting developments adopted by the Group
The Group adopted the amendments to IAS 7 and IFRS 7 “Supplier Finance Arrangements” from reporting period beginning 1 January 2024. The amendments introduce additional disclosure requirements for companies that enter supplier finance arrangements. The company will apply these amendments in the 2024 Annual Report.
All other standards or amendments to the standards that have been issued by the IASB and were effective 1 January 2024 were not applicable or material to Unilever.
v3.24.2
Segment information - Business Groups (Tables)
 6 Months Ended
Jun. 30, 2024
Disclosure of operating segments [abstract]  
Summary of Operating Results by Reportable Segments
Second QuarterBeauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Turnover (€ million)
20233,143 3,519 3,057 3,260 2,760 15,739 
20243,343 3,531 3,113 3,289 2,815 16,091 
Change (%)6.3 0.3 1.8 0.9 2.0 2.2 
First HalfBeauty & WellbeingPersonal CareHome CareNutritionIce CreamTotal
Turnover (€ million)
20236,225 6,911 6,205 6,601 4,486 30,428 
20246,539 6,953 6,328 6,687 4,610 31,117 
Change (%)5.1 0.6 2.0 1.3 2.8 2.3 
Operating profit (€ million)
20231,237 1,691 731 1,213 644 5,516 
20241,269 1,696 963 1,423 597 5,948 
Underlying operating profit (€ million)
20231,179 1,381 763 1,214 671 5,208 
20241,305 1,601 1,031 1,491 672 6,100 
v3.24.2
Segment information - Geographical area (Tables)
 6 Months Ended
Jun. 30, 2024
Disclosure of operating segments [abstract]  
Summary of Operating Results by Geographical Areas
3.Segment information - Geographical area
Second QuarterAsia Pacific AfricaThe AmericasEuropeTotal
Turnover (€ million)
20236,6995,7003,34015,739
20246,7325,9243,43516,091
Change (%)0.5 3.9 2.9 2.2 
First HalfAsia Pacific AfricaThe AmericasEuropeTotal
Turnover (€ million)
202313,421 10,956 6,051 30,428 
202413,370 11,463 6,284 31,117 
Change (%)(0.4)4.6 3.8 2.3 
v3.24.2
Taxation (Tables)
 6 Months Ended
Jun. 30, 2024
Income taxes paid (refund) [abstract]  
Summary of Tax Effects of Components of Other Comprehensive Income
Tax effects of components of other comprehensive income were as follows:
First half
20242023
€ millionBefore taxTax (charge)/creditAfter taxBefore taxTax (charge)/creditAfter tax
Gains/(losses) on:
Equity instruments at fair value through other comprehensive income31 – 31 (34)– (34)
Cash flow hedges63 (5)58 (20)(2)(22)
Remeasurements of defined benefit pension plans242 (41)201 (90)43 (47)
Currency retranslation gains/(losses)772 (16)756 (535)(20)(555)
Other comprehensive income1,108 (62)1,046 (679)21 (658)
v3.24.2
Earnings per share (Tables)
 6 Months Ended
Jun. 30, 2024
Earnings per share [abstract]  
Schedule of Computation of Earnings Per Share and Summary of Movements in Shares
Earnings per share for total operations for the six months were calculated as follows:
First Half
20242023
EPS – Basic
Net profit attributable to shareholders’ equity (€ million)3,7013,548
Average number of shares (millions of share units)2,499.92,523.9
EPS – basic (€)1.481.41
EPS – Diluted
Net profit attributable to shareholders’ equity (€ million)3,7013,548
Adjusted average number of shares (millions of share units)2,511.02,536.8
EPS – diluted (€)1.471.40
During the period the following movements in shares have taken place:
Millions
Number of shares at 31 December 2023 (net of treasury shares)2,499.0 
Shares repurchased under the share buyback programme(7.3)
Net movements in shares under incentive schemes3.7 
Number of shares at 30 June 2024 (net of treasury shares)2,495.4 
v3.24.2
Acquisitions and disposals (Tables)
 6 Months Ended
Jun. 30, 2024
Disclosure of detailed information about business combination [abstract]  
Disclosure of Detailed Information about Deal Completion and Acquired Business
In the first half of 2024, the Group completed the following business acquisitions and disposals:
Deal completion dateAcquired/disposed business
1 February 2024
Acquired 91.88% of K18, a U.S. based premium hair care brand. The acquisition complements Unilever’s existing Beauty and Wellbeing portfolio, with a range of high-quality, hair care products.
1 June 2024
Sold Elida Beauty to Yellow Wood Partners LLC. Elida Beauty comprises more than 20 beauty and personal care brands, such as Q-Tips, Caress, Timotei and TIGI.
v3.24.2
Financial instruments (Tables)
 6 Months Ended
Jun. 30, 2024
Disclosure of detailed information about financial instruments [abstract]  
Schedule of Cash Resources and Other Financial Assets
The Group’s Treasury function aims to protect the Group’s financial investments, while maximising returns. The fair value of financial assets is the same as the carrying amount for 2024 and 2023. The Group’s cash resources and
other financial assets are shown below.
30 June 2024
31 December 2023
30 June 2023
CurrentNon-currentTotalCurrentNon-currentTotalCurrentNon-currentTotal
Cash and cash equivalents
Cash at bank and in hand3,601 – 3,601 2,862 – 2,862 2,790 – 2,790 
Short-term deposits(a)
981 – 981 1,181 – 1,181 1,804 – 1,804 
Other cash equivalents(b)
388 – 388 116 – 116 400 – 400 
4,970 – 4,970 4,159 – 4,159 4,994 – 4,994 
Other financial assets
Financial assets at amortised cost(c)
835 560 1,395 961 454 1,415 727 352 1,079 
Financial assets at fair value through other comprehensive income(d)
61 525 586 151 458 609 – 438 438 
Financial assets at fair value through profit or loss:
  Derivatives79 39 118 37 75 112 36 31 67 
  Other(e)
470 382 852 582 399 981 613 399 1,012 
1,445 1,506 2,951 1,731 1,386 3,117 1,376 1,220 2,596 
Total financial assets(f)
6,415 1,506 7,921 5,890 1,386 7,276 6,370 1,220 7,590 
(a) Short-term deposits typically have maturity of up to 3 months.
(b) Other cash equivalents include investments in overnight funds and marketable securities.
(c) Current financial assets at amortised cost include short term deposits with banks with maturities longer than three months excluding deposits which are part of a recognised cash management process and loans to joint venture entities. Non-current financial assets at amortised cost include judicial deposits of €212 million (31 December 2023: €227 million; 30 June 2023: €228 million).
(d) Included within non-current financial assets at fair value through other comprehensive income are equity investments.
(e) Other financial assets at fair value through profit or loss include money market funds, marketable securities, other capital market instruments
and investments in companies and financial institutions in North America, North Asia, South Asia and Europe.
(f) Financial assets exclude trade and other current receivables.
Summary of Fair Values of Financial Assets and Financial Liabilities The following tables summarise the fair values and carrying amounts of financial instruments and the fair value calculations by category.
€ millionFair valueCarrying amount
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Financial assets
Cash and cash equivalents4,970 4,159 4,994 4,970 4,159 4,994 
Financial assets at amortised cost1,395 1,415 1,079 1,395 1,415 1,079 
Financial assets at fair value through other comprehensive income586 609 438 586 609 438 
Financial assets at fair value through profit and loss:
Derivatives118 112 67 118 112 67 
Other852 981 1,012 852 981 1,012 
7,921 7,276 7,590 7,921 7,276 7,590 
Financial liabilities
Bank loans and overdrafts(460)(506)(606)(460)(506)(606)
Bonds and other loans(27,836)(26,112)(26,265)(28,729)(26,692)(27,599)
Lease liabilities(1,358)(1,395)(1,428)(1,358)(1,395)(1,428)
Derivatives(537)(494)(618)(537)(494)(618)
Other financial liabilities(570)(535)(457)(570)(535)(457)
(30,761)(29,042)(29,374)(31,654)(29,622)(30,708)
Summary of Assets and Liabilities Carried at Fair Value, Classification of Fair Value Calculations by Category
€ million
As at 30 June 2024
As at 31 December 2023
As at 30 June 2023
Level 1Level 2Level 3Level 1Level 2Level 3Level 1Level 2Level 3
Assets at fair value
Financial assets at fair value through other comprehensive income70 4 512 163 4 442 14 3 421 
Financial assets at fair value through profit or loss:
Derivatives(a)
– 192 – – 149 – – 142 – 
Other470 – 382 582 – 399 613 – 399 
Liabilities at fair value
Derivatives(b)
– (586)– – (559)– – (718)– 
Contingent consideration– – (8)– – (157)– – (123)
(a) Includes €74 million (31 December 2023: €37 million; 30 June 2023: €75 million) derivatives, reported within trade receivables, that hedge trading activities.
(b) Includes €(49) million (31 December 2023: €(65) million; 30 June 2023: €(100) million) derivatives, reported within trade creditors, that hedge trading activities.
v3.24.2
Dividends (Tables)
 6 Months Ended
Jun. 30, 2024
Dividends [Abstract]  
Summary of Dividends on Ordinary Capital
The following amounts will be paid in respect of this quarterly interim dividend on the relevant payment date:
Per Unilever PLC ordinary share (traded on the London Stock Exchange):£0.3696
Per Unilever PLC ordinary share (traded on Euronext in Amsterdam):€0.4396
Per Unilever PLC American Depositary Receipt:US$0.4773
Summary of Quarterly Dividend Calendar
The quarterly dividend calendar for the remainder of 2024 will be as follows:

Announcement DateEx-Dividend DateRecord DatePayment Date
Q2 2024 Dividend25 July 202408 August 202409 August 202406 September 2024
Q3 2024 Dividend24 October 202407 November 202408 November 202406 December 2024
v3.24.2
Segment information - Business Groups (Details) - EUR (€)
€ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disclosure of operating segments [line items]        
Revenue € 16,091 € 15,739 € 31,117 € 30,428
Percentage Of Turnover Growth 2.20%   2.30%  
Profit (loss) from operating activities     € 5,948 5,516
Underlying Operating Profit     6,100 5,208
Beauty & Wellbeing        
Disclosure of operating segments [line items]        
Revenue € 3,343 3,143 € 6,539 6,225
Percentage Of Turnover Growth 6.30%   5.10%  
Profit (loss) from operating activities     € 1,269 1,237
Underlying Operating Profit     1,305 1,179
Personal Care        
Disclosure of operating segments [line items]        
Revenue € 3,531 3,519 € 6,953 6,911
Percentage Of Turnover Growth 0.30%   0.60%  
Profit (loss) from operating activities     € 1,696 1,691
Underlying Operating Profit     1,601 1,381
Home Care        
Disclosure of operating segments [line items]        
Revenue € 3,113 3,057 € 6,328 6,205
Percentage Of Turnover Growth 1.80%   2.00%  
Profit (loss) from operating activities     € 963 731
Underlying Operating Profit     1,031 763
Nutrition        
Disclosure of operating segments [line items]        
Revenue € 3,289 3,260 € 6,687 6,601
Percentage Of Turnover Growth 0.90%   1.30%  
Profit (loss) from operating activities     € 1,423 1,213
Underlying Operating Profit     1,491 1,214
Ice Cream        
Disclosure of operating segments [line items]        
Revenue € 2,815 € 2,760 € 4,610 4,486
Percentage Of Turnover Growth 2.00%   2.80%  
Profit (loss) from operating activities     € 597 644
Underlying Operating Profit     € 672 € 671
v3.24.2
Segment information - Geographical area (Details) - EUR (€)
€ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disclosure of operating segments [line items]        
Revenue € 16,091 € 15,739 € 31,117 € 30,428
Percentage Of Turnover Growth 2.20%   2.30%  
Asia Pacific Africa        
Disclosure of operating segments [line items]        
Revenue € 6,732 6,699 € 13,370 13,421
Percentage Of Turnover Growth 0.50%   (0.40%)  
The Americas        
Disclosure of operating segments [line items]        
Revenue € 5,924 5,700 € 11,463 10,956
Percentage Of Turnover Growth 3.90%   4.60%  
Europe        
Disclosure of operating segments [line items]        
Revenue € 3,435 € 3,340 € 6,284 € 6,051
Percentage Of Turnover Growth 2.90%   3.80%  
v3.24.2
Taxation - Narrative (Details)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Income taxes paid (refund) [abstract]    
Average effective tax rate (in percent) 28.60% 26.90%
v3.24.2
Taxation - Summary of Tax Effects of Components of Other Comprehensive Income (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Before tax    
Equity instruments at fair value through other comprehensive income € 31 € (34)
Cash flow hedges 63 (20)
Remeasurements of defined benefit pension plans 242 (90)
Currency retranslation gains/(losses) 772 (535)
Other comprehensive income 1,108 (679)
Tax (charge)/credit    
Equity instruments at fair value through other comprehensive income 0 0
Cash flow hedges (5) (2)
Remeasurements of defined benefit pension plans (41) 43
Currency retranslation gains/(losses) (16) (20)
Other comprehensive income (62) 21
After tax    
Equity instruments at fair value through other comprehensive income 31 (34)
Cash flow hedges 58 (22)
Remeasurements of defined benefit pension plans 201 (47)
Currency retranslation gains/(losses) [1] 756 (555)
Other comprehensive income € 1,046 € (658)
[1] 2024 includes a hyperinflation adjustment of €680 million (2023: €247 million) in relation to Argentina and Turkey.
v3.24.2
Earnings per share - Schedule of Computation of Earnings Per Share (Details) - EUR (€)
€ / shares in Units, € in Millions, shares in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
EPS – Basic    
Net profit attributable to shareholders’ equity (€ million) € 3,701 € 3,548
Average number of shares (in millions of shares) 2,499.9 2,523.9
EPS - basic (in euros per share) € 1.48 € 1.41
EPS – Diluted    
Net profit attributable to shareholders’ equity (€ million) € 3,701 € 3,548
Diluted average number of shares (in millions of shares) 2,511.0 2,536.8
EPS - diluted (in euros per share) € 1.47 € 1.40
v3.24.2
Earnings per share - Summary of Movements in Shares (Details)
shares in Millions
 6 Months Ended
Jun. 30, 2024
shares
Reconciliation of number of shares outstanding [abstract]  
Number of shares outstanding at beginning of period (in shares) 2,499.0
Shares repurchased under the share buyback programme (in shares) (7.3)
Net movements in shares under incentive schemes (in shares) 3.7
Number of shares outstanding at end of period (in shares) 2,495.4
v3.24.2
Acquisitions and disposals - Disclosure of Detailed Information about Deal Completion and Acquired Business (Details) - brand
Jun. 01, 2024
Feb. 01, 2024
Elida Beauty    
Disclosure of detailed information about business combination [line items]    
Number of brands 20  
K18    
Disclosure of detailed information about business combination [line items]    
Percentage of voting equity interests acquired   91.88%
v3.24.2
Acquisitions and disposals - Narrative (Details) - Elida Beauty
€ in Millions
Jun. 01, 2024
EUR (€)
Disclosure of analysis of single amount of discontinued operations [line items]  
Consideration received € 588
Gain on disposal of Elida Beauty € 151
v3.24.2
Share buyback (Details) - EUR (€)
€ in Millions
 6 Months Ended
May 17, 2024
Feb. 08, 2024
Jun. 30, 2024
Jun. 30, 2023
Disclosure of reserves within equity [line items]        
Share buyback program, authorized amount € 850      
Number of shares acquired (in shares)     7,315,036  
Repurchase of shares [1]     € (375) € (753)
Other reserves        
Disclosure of reserves within equity [line items]        
Repurchase of shares [1]     € (375) € (753)
Top of range        
Disclosure of reserves within equity [line items]        
Share buyback program, authorized amount   € 1,500    
[1] Repurchase of shares reflects the cost of acquiring ordinary shares as part of the share buyback program announced on 10 February 2022 and 8 February 2024.
v3.24.2
Financial instruments - Schedule of Cash Resources and Other Financial Assets (Details) - EUR (€)
€ in Millions
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Cash and cash equivalents, current      
Cash at bank and in hand € 3,601 € 2,862 € 2,790
Short-term deposits 981 1,181 1,804
Other cash equivalents 388 116 400
Cash and cash equivalents 4,970 4,159 4,994
Other financial assets, current      
Financial assets at amortised cost 835 961 727
Financial assets at fair value through other comprehensive income 61 151 0
Other financial assets 1,445 1,731 1,376
Current financial assets 6,415 5,890 6,370
Cash and cash equivalents, non-current      
Cash at bank and in hand 0 0 0
Short-term deposits 0 0 0
Other cash equivalents 0 0 0
Cash and cash equivalents 0 0 0
Other financial assets, non-current      
Financial assets at amortised cost 560 454 352
Financial assets at fair value through other comprehensive income 525 458 438
Other financial assets 1,506 1,386 1,220
Non-current financial assets 1,506 1,386 1,220
Cash and cash equivalents, total      
Cash at bank and in hand 3,601 2,862 2,790
Short-term deposits 981 1,181 1,804
Other cash equivalents 388 116 400
Cash and cash equivalents 4,970 4,159 4,994
Other financial assets, total      
Financial assets at amortised cost 1,395 1,415 1,079
Financial assets at fair value through other comprehensive income 586 609 438
Other financial assets 2,951 3,117 2,596
Financial assets 7,921 7,276 7,590
Financial assets at amortised cost 560 454 352
Judicial deposits      
Other financial assets, non-current      
Financial assets at amortised cost 212 227 228
Other financial assets, total      
Financial assets at amortised cost 212 227 228
Derivatives      
Other financial assets, current      
Financial assets at fair value through profit or loss 79 37 36
Other financial assets, non-current      
Financial assets at fair value through profit or loss 39 75 31
Other financial assets, total      
Financial assets at fair value through profit or loss 118 112 67
Other      
Other financial assets, current      
Financial assets at fair value through profit or loss 470 582 613
Other financial assets, non-current      
Financial assets at fair value through profit or loss 382 399 399
Other financial assets, total      
Financial assets at fair value through profit or loss € 852 € 981 € 1,012
v3.24.2
Financial instruments - Summary of Fair Values of Financial Assets and Financial Liabilities (Details) - EUR (€)
€ in Millions
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Financial assets      
Cash and cash equivalents € 4,970 € 4,159 € 4,994
Financial assets at amortised cost 1,395 1,415 1,079
Financial assets at fair value through other comprehensive income 586 609 438
Financial assets 7,921 7,276 7,590
Derivatives      
Financial assets      
Financial assets at fair value through profit or loss 118 112 67
Other      
Financial assets      
Financial assets at fair value through profit or loss 852 981 1,012
Fair value      
Financial assets      
Cash and cash equivalents 4,970 4,159 4,994
Financial assets at amortised cost 1,395 1,415 1,079
Financial assets at fair value through other comprehensive income 586 609 438
Financial assets 7,921 7,276 7,590
Financial liabilities      
Bank loans and overdrafts (460) (506) (606)
Bonds and other loans (27,836) (26,112) (26,265)
Lease liabilities (1,358) (1,395) (1,428)
Derivatives (537) (494) (618)
Other financial liabilities (570) (535) (457)
Financial liabilities (30,761) (29,042) (29,374)
Fair value | Derivatives      
Financial assets      
Financial assets at fair value through profit or loss 118 112 67
Fair value | Other      
Financial assets      
Financial assets at fair value through profit or loss 852 981 1,012
Carrying amount      
Financial assets      
Cash and cash equivalents 4,970 4,159 4,994
Financial assets at amortised cost 1,395 1,415 1,079
Financial assets at fair value through other comprehensive income 586 609 438
Financial assets 7,921 7,276 7,590
Financial liabilities      
Bank loans and overdrafts (460) (506) (606)
Bonds and other loans (28,729) (26,692) (27,599)
Lease liabilities (1,358) (1,395) (1,428)
Derivatives (537) (494) (618)
Other financial liabilities (570) (535) (457)
Financial liabilities (31,654) (29,622) (30,708)
Carrying amount | Derivatives      
Financial assets      
Financial assets at fair value through profit or loss 118 112 67
Carrying amount | Other      
Financial assets      
Financial assets at fair value through profit or loss € 852 € 981 € 1,012
v3.24.2
Financial instruments - Summary of Assets and Liabilities Carried at Fair Value, Classification of Fair Value Calculations by Category (Details) - EUR (€)
€ in Millions
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Assets at fair value      
Financial assets at fair value through other comprehensive income € 586 € 609 € 438
Derivatives      
Financial assets at fair value through profit and loss:      
Other 118 112 67
Other      
Financial assets at fair value through profit and loss:      
Other 852 981 1,012
Fair value      
Assets at fair value      
Financial assets at fair value through other comprehensive income 586 609 438
Liabilities at fair value      
Derivatives financial assets, reported within trade receivables 74 37 75
Derivatives financial liabilities, reported within trade creditors (49) (65) (100)
Fair value | Derivatives      
Financial assets at fair value through profit and loss:      
Other 118 112 67
Fair value | Other      
Financial assets at fair value through profit and loss:      
Other 852 981 1,012
Fair value | Level 1      
Assets at fair value      
Financial assets at fair value through other comprehensive income 70 163 14
Fair value | Level 1 | Derivatives      
Liabilities at fair value      
Derivatives 0 0 0
Fair value | Level 1 | Financial liabilities at fair value      
Liabilities at fair value      
Contingent consideration 0 0 0
Fair value | Level 1 | Derivatives      
Financial assets at fair value through profit and loss:      
Derivatives 0 0 0
Fair value | Level 1 | Other      
Financial assets at fair value through profit and loss:      
Other 470 582 613
Fair value | Level 2      
Assets at fair value      
Financial assets at fair value through other comprehensive income 4 4 3
Fair value | Level 2 | Derivatives      
Liabilities at fair value      
Derivatives (586) (559) (718)
Fair value | Level 2 | Financial liabilities at fair value      
Liabilities at fair value      
Contingent consideration 0 0 0
Fair value | Level 2 | Derivatives      
Financial assets at fair value through profit and loss:      
Derivatives 192 149 142
Fair value | Level 2 | Other      
Financial assets at fair value through profit and loss:      
Other 0 0 0
Fair value | Level 3      
Assets at fair value      
Financial assets at fair value through other comprehensive income 512 442 421
Fair value | Level 3 | Derivatives      
Liabilities at fair value      
Derivatives 0 0 0
Fair value | Level 3 | Financial liabilities at fair value      
Liabilities at fair value      
Contingent consideration (8) (157) (123)
Fair value | Level 3 | Derivatives      
Financial assets at fair value through profit and loss:      
Derivatives 0 0 0
Fair value | Level 3 | Other      
Financial assets at fair value through profit and loss:      
Other € 382 € 399 € 399
v3.24.2
Dividends - Summary of Dividends on Ordinary Capital (Details) - 3 months ended Jun. 30, 2024 - Unilever PLC
£ / shares
€ / shares
$ / shares
Disclosure Of Dividends [Line Items]      
Dividend per share (in pound, euro and dollar per share) | (per share) £ 0.3696 € 0.4396  
Per Unilever PLC ordinary share | Traded on the London Stock Exchange      
Disclosure Of Dividends [Line Items]      
Dividend per share (in pound, euro and dollar per share) | £ / shares £ 0.3696    
Per Unilever PLC ordinary share | Traded on Euronext in Amsterdam      
Disclosure Of Dividends [Line Items]      
Dividend per share (in pound, euro and dollar per share) | € / shares   € 0.4396  
Per Unilever PLC American Depositary Receipt      
Disclosure Of Dividends [Line Items]      
Dividend per share (in pound, euro and dollar per share) | $ / shares     $ 0.4773
v3.24.2
Dividends - Narrative (Details) - 3 months ended Jun. 30, 2024
£ / shares
€ / shares
Unilever PLC    
Disclosure Of Dividends [Line Items]    
Dividend per share (in pound, euro and dollar per share) | (per share) £ 0.3696 € 0.4396
Unilever Plc Gbp (PK) (USOTC:UNLYF)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Unilever Plc Gbp (PK) Charts.
Unilever Plc Gbp (PK) (USOTC:UNLYF)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Unilever Plc Gbp (PK) Charts.